<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58567</article-id><article-id pub-id-type="doi">10.7554/eLife.58567</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group></article-categories><title-group><article-title>Investigating pleiotropic effects of statins on ischemic heart disease in the UK Biobank using Mendelian randomisation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-1468"><name><surname>Schooling</surname><given-names>CM</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9933-5887</contrib-id><email>cms1@hku.hk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188302"><name><surname>Zhao</surname><given-names>JV</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188303"><name><surname>Au Yeung</surname><given-names>SL</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188304"><name><surname>Leung</surname><given-names>GM</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>City University of New York, Graduate School of Public Health and Health Policy</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewing Editor</role><aff><institution>University of Melbourne</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution>University of Zurich</institution><country>Switzerland</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>25</day><month>08</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e58567</elocation-id><history><date date-type="received" iso-8601-date="2020-05-04"><day>04</day><month>05</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-08-13"><day>13</day><month>08</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Schooling et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Schooling et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-58567-v2.pdf"/><abstract><p>We examined whether specifically statins, of the major lipid modifiers (statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and ezetimibe) have pleiotropic effects on ischemic heart disease (IHD) via testosterone in men or women. As a validation, we similarly assessed whether a drug that unexpectedly likely increases IHD also operates via testosterone. Using previously published genetic instruments we conducted a sex-specific univariable and multivariable Mendelian randomization study in the UK Biobank, including 179918 men with 25410 IHD cases and 212080 women with 12511 IHD cases. Of these three lipid modifiers, only genetically mimicking the effects of statins in men affected testosterone, which partly mediated effects on IHD. Correspondingly, genetically mimicking effects of anakinra on testosterone and IHD presented a reverse pattern to that for statins. These insights may facilitate the development of new interventions for cardiovascular diseases as well as highlighting the importance of sex-specific explanations, investigations, prevention and treatment.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>statin</kwd><kwd>cardiovascular</kwd><kwd>pleiotropy</kwd><kwd>sex-specific</kwd><kwd>testosterone</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><funding-statement>The authors declare that there was no funding for this work</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Identifying why statins differ from other major lipid modifiers has revealed a new modifiable target of intervention for cardiovascular disease relevant to both drug development and optimal statin use.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Statins are the first-line lipid modifier for reducing cardiovascular morbidity and mortality (<xref ref-type="bibr" rid="bib49">Ray et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">Michos et al., 2019</xref>). Statins have revolutionized the prevention and treatment of cardiovascular disease, and inspired the development of a range of effective interventions targeting the reduction of low-density lipoprotein (LDL)-cholesterol. Statins have long been suspected of having additional beneficial effects beyond lipid modulation (<xref ref-type="bibr" rid="bib60">Schonbeck and Libby, 2004</xref>), such as on inflammation (<xref ref-type="bibr" rid="bib60">Schonbeck and Libby, 2004</xref>), another potential target for reducing cardiovascular disease (<xref ref-type="bibr" rid="bib1">Aday and Ridker, 2018</xref>). Meta-analysis of randomized controlled trials (RCTs) suggests statins are more effective at reducing mortality than proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors or ezetimibe (<xref ref-type="bibr" rid="bib59">Schmidt et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Khan et al., 2018</xref>). However, these findings may be more apparent than real, stemming from differences in trial design, such as shorter duration of the PCSK9 inhibitor trials (<xref ref-type="bibr" rid="bib31">Khan et al., 2018</xref>), the predominance of industry funded statin trials (<xref ref-type="bibr" rid="bib26">Hobbs et al., 2016</xref>) or the difficulty of interpreting trials of ‘soft’ events when the treatment affects diagnostically relevant criteria, that is lipid levels (<xref ref-type="bibr" rid="bib69">Schooling and Zhao, 2019</xref>). To investigate this anomaly, a previous study conducted a systematic agnostic scan of metabolic profile in a trial of statins compared to a PCSK9 inhibitor, which found few differences (<xref ref-type="bibr" rid="bib73">Sliz et al., 2018</xref>). While characterization of the metabolic effects of statins suggested extensive effects on lipids and fatty acids (<xref ref-type="bibr" rid="bib82">Würtz et al., 2016</xref>); these investigations were not able to include a factor which has previously been proposed as contributing to statin’s effectiveness, that is effects on male hormones (<xref ref-type="bibr" rid="bib61">Schooling et al., 2013</xref>), although questions have been raised as to whether statins are as effective in women as men (<xref ref-type="bibr" rid="bib46">Plakogiannis and Arif, 2016</xref>). However, meta-analysis of the available trial evidence suggests similar relative benefits of LDL-cholesterol reduction by statins for men and women (<xref ref-type="bibr" rid="bib23">Fulcher et al., 2015</xref>), although the trials mainly concern men (73.2%) which may preclude detection of important sex differences. Men are also at substantially higher risk than women (<xref ref-type="bibr" rid="bib18">Ezzati et al., 2015</xref>) giving larger absolute benefits in men than women at the same reduction in relative risk.</p><p>RCTs are not usually designed or powered to test mediating mechanisms. In addition, trials of statins on cardiovascular disease outcomes designed to be sex-specific are lacking. To assess a potential pathway by which statins might additionally operate, we used Mendelian randomization (MR), an observational study design that avoids confounding by taking advantage of the random allocation of genetic material at conception (<xref ref-type="bibr" rid="bib74">Smith and Ebrahim, 2003</xref>), here specifically genetic variants mimicking effects of lipid modifiers. This random allocation at conception also avoids selection bias as long as few deaths have occurred between randomization and recruitment due to exposure, outcome, or other causes, that is competing risk, of the outcome (<xref ref-type="bibr" rid="bib67">Schooling et al., 2020</xref>). So, here we focused on ischemic heart disease (IHD) (<xref ref-type="bibr" rid="bib30">Kesteloot and Decramer, 2008</xref>), using the UK Biobank (<xref ref-type="bibr" rid="bib13">Collins, 2012</xref>) to investigate whether testosterone mediated any of the effects of statins, PCSK9 inhibitors or ezetimibe on IHD in men or women using univariable and multivariable MR. As a further test, given some anti-inflammatories have also been shown to have opposite effects on male hormones compared to statins, specifically the interleukin one receptor antagonist (IL-1Ra), anakinra (<xref ref-type="bibr" rid="bib16">Ebrahimi et al., 2018</xref>), we assessed whether the genetic variants mimicking effects of anakinra or tocilizumab targeting the interleukin six receptor (IL-6r) had opposite patterns of effects on testosterone and IHD (<xref ref-type="bibr" rid="bib1">Aday and Ridker, 2018</xref>; <xref ref-type="bibr" rid="bib75">Swerdlow et al., 2012</xref>; <xref ref-type="bibr" rid="bib27">Interleukin 1 Genetics Consortium, 2015</xref>) to statins. <xref ref-type="fig" rid="fig1">Figure 1</xref> illustrates the possible additional effects of statins, anakinra or tocilizumab on IHD via male hormones in the context of the well-established benefits of statins, PCSK9 inhibitors and ezetimibe acting via LDL-cholesterol and of anti-inflammatories in IHD.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Directed acyclic graph showing the well-established protective effects of lipid modifiers and anti-inflammatories on IHD (solid lines) and possible additional pathways (dashed lines) investigated here.</title><p>Green indicates a lowering effect, red indicates an increasing effect.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58567-fig1-v2.tif"/></fig></sec><sec id="s2" sec-type="results"><title>Results</title><p>The six single neucleotide polymorphisms (SNPs) mimicking effects of statin (rs12916, rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 from <italic>HMGCR</italic>) (<xref ref-type="bibr" rid="bib20">Ference et al., 2019</xref>) were all correlated (r<sup>2</sup> &gt;0.13). In the main analysis we used only the lead SNP, rs12916. Of the 7 SNPs mimicking effects of PCSK9 inhibitors (rs11206510, rs2149041, rs7552841, rs10888897, rs2479394, rs2479409 and rs562556 from <italic>PCSK9</italic>) (<xref ref-type="bibr" rid="bib20">Ference et al., 2019</xref>), the three independently (r<sup>2</sup> &lt;0.05) and most strongly associated with LDL-cholesterol (rs11206510, rs2149041 and rs7552841) were used in the main analysis. Of the 5 SNPs mimicking effects of ezetimibe (rs10260606 (proxy of rs2073547, r<sup>2</sup> = 0.99), rs2300414, rs10234070, rs7791240, rs217386 from <italic>NCP1L1</italic>) (<xref ref-type="bibr" rid="bib20">Ference et al., 2019</xref>), two SNPs (rs2300414 and rs10234070) were discarded because their F-statistic for LDL-cholesterol was &lt;10. The remaining three SNPs were all correlated at r<sup>2</sup> &gt;0.05. rs2073547 was used in the main analysis because it had the strongest association with LDL-cholesterol. <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref> shows the associations with LDL-cholesterol by sex for the independent SNPs used to mimic effects of statins, PCSK9 inhibitors and ezetimibe. <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref> shows the associations of the two SNPs mimicking effects of the anti-inflammatory, anakinra, (rs6743376 and rs1542176 (r<sup>2</sup> &lt;0.001)) with IL-1Ra and the associations of the SNP (rs7529229), mimicking effects of tocilizumab use, with IL-6r.</p><p>There were 179,918 men with 25,410 cases of IHD and 212,080 women with 12,511 cases of IHD in the UK Biobank.</p><sec id="s2-1"><title>Instrument strength</title><p>The F-statistics for SNPs used to genetically mimic the effects of statins, PCSK9 inhibitors and ezetimibe were all &gt;10 in men and women (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>), as were the F-statistics for the SNPs used to mimic the effects of anakinra and tocilizumab (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). The F-statistics for the 125 and 254 SNPs predicting testosterone in men and women were all greater than 10, with mean 128.6 and 83.3, respectively.</p></sec><sec id="s2-2"><title>Sex-specific associations of genetically mimicked lipid modifiers with testosterone</title><p>Genetically mimicked effects of statins reduced testosterone in men but not women (<xref ref-type="table" rid="table1">Table 1</xref>). Genetically mimicked effects of PCSK9 inhibitors and of ezetimibe did not affect testosterone in men or women (<xref ref-type="table" rid="table1">Table 1</xref>). Findings were similar in sensitivity analysis including correlated SNPs, where available (<xref ref-type="table" rid="table1">Table 1</xref>). PCSK9 inhibitors and ezetimibe were not investigated further, given the lack of association with testosterone in men and women.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Sex-specific Mendelian randomization estimates (where possible) for effects of genetically mimicked statins, PCSK9 inhibitor and ezetimibe (in effect sizes of LDL-cholesterol) on testosterone (effect size) in men and women using the UK Biobank .</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top"/><th valign="top"/><th valign="top"/><th colspan="4" valign="top">Mendelian Randomization estimates</th></tr><tr><th valign="top"/><th valign="top">Therapy</th><th valign="top"># SNPs</th><th valign="top">Method</th><th valign="top">Beta</th><th valign="top">95% CI</th><th valign="top">P value</th><th valign="top">MR-Egger intercept p-value</th></tr></thead><tbody><tr><td valign="top">Men</td><td valign="top">Statin</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">−0.15</td><td valign="top">−0.23 to −0.06</td><td valign="top">0.001</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Statin</td><td valign="top">6</td><td valign="top">Inverse variance weighted</td><td valign="top">−0.15</td><td valign="top">−0.23 to −0.07</td><td valign="top">0.0005</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">Inverse variance weighted</td><td valign="top">0.04</td><td valign="top">−0.11 to 0.18</td><td valign="top">0.63</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">Weighted median</td><td valign="top">0.07</td><td valign="top">−0.13 to 0.27</td><td valign="top">0.29</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">MR-Egger</td><td valign="top">0.34</td><td valign="top">0.09 to 0.60</td><td valign="top">0.01</td><td valign="top">−0.01 (0.01)</td></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">7</td><td valign="top">Inverse variance weighted</td><td valign="top">0.05</td><td valign="top">−0.05 to 0.15</td><td valign="top">0.29</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">0.04</td><td valign="top">−0.15 to 0.23</td><td valign="top">0.68</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">3</td><td valign="top">Inverse variance weighted</td><td valign="top">0.05</td><td valign="top">−0.12 to 0.22</td><td valign="top">0.55</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">3</td><td valign="top">Weighted median</td><td valign="top">0.03</td><td valign="top">−0.13 to 0.18</td><td valign="top">0.72</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">3</td><td valign="top">MR-Egger</td><td valign="top">0.24</td><td valign="top">−0.52 to 1.0</td><td valign="top">0.54</td><td valign="top">−0.01 (0.52)</td></tr><tr><td valign="top">Women</td><td valign="top">Statin</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">0.04</td><td valign="top">−0.06 to 0.14</td><td valign="top">0.45</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Statin</td><td valign="top">6</td><td valign="top">Inverse variance weighted</td><td valign="top">0.03</td><td valign="top">−0.07 to 0.13</td><td valign="top">0.52</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">Inverse variance weighted</td><td valign="top">0.01</td><td valign="top">−0.11 to 0.14</td><td valign="top">0.85</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">Weighted median</td><td valign="top">0.01</td><td valign="top">−0.13 to 0.15</td><td valign="top">0.91</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">3</td><td valign="top">MR-Egger</td><td valign="top">0.09</td><td valign="top">−0.38 to 0.56</td><td valign="top">0.71</td><td valign="top">−0.003 (0.74)</td></tr><tr><td valign="top"/><td valign="top">PCSK9 inhibitor</td><td valign="top">7</td><td valign="top">Inverse variance weighted</td><td valign="top">−0.004</td><td valign="top">−0.14 to 0.13</td><td valign="top">0.95</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">0.18</td><td valign="top">−0.05 to 0.40</td><td valign="top">0.12</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">ezetimibe</td><td valign="top">3</td><td valign="top">Inverse variance weighted</td><td valign="top">0.12</td><td valign="top">−0.08 to 0.31</td><td valign="top">0.24</td><td valign="top"/></tr></tbody></table><table-wrap-foot><fn><p>One statin SNP is rs12916, and six statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account their correlations.</p><p>Three PCSK9 inhibitor SNPs are rs11206510, rs2149041 and rs7552841, and 7 PCSK9 inhibitor SNPs additionally included rs10888897, rs2479394, rs2479409 and, rs562556 taking into account all their correlations.</p></fn><fn><p>One ezetimibe SNP is rs2073547 (proxied by rs10260606), and three ezetimibe SNPs additionally included rs7791240 and rs217386 taking into account all their correlations.</p><p>The unit of LDL-cholesterol is approximately 0.83 mm/L. An effect size of testosterone is approximately, 0.23 nmol/L in women (<xref ref-type="bibr" rid="bib24">Haring et al., 2012</xref>) and 3.1 nmol/L in men (<xref ref-type="bibr" rid="bib39">Mohr et al., 2005</xref>).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3"><title>Sex-specific associations of genetically mimicked statin use and testosterone with IHD</title><p>Genetically mimicked effects of statins reduced the risk of IHD in men and possibly women (<xref ref-type="table" rid="table2">Table 2</xref>) using IVW. Steiger filtering indicated directionality from testosterone to IHD in men and women. Genetically predicted testosterone was positively associated with IHD in men, but was not significantly associated with IHD in women, with similar estimates using IVW, the weighted median and MR-Egger. MR-Egger intercepts did not suggest the IVW estimates were invalid, but had wider confidence intervals (<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Mendelian randomization estimates for effects of genetically mimicked statins (effect sizes of LDL-cholesterol) and of genetically predicted testosterone (effect size) on IHD in men and women using the UK Biobank.</title><p> <supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Genetic associations for men.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-58567-table2-data1-v2.csv"/></supplementary-material> </p><p> <supplementary-material id="table2sdata2"><label>Table 2—source data 2.</label><caption><title>genetic associations for women.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-58567-table2-data2-v2.csv"/></supplementary-material> </p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top"/><th valign="top"/><th valign="top"/><th colspan="4" valign="top">Mendelian randomization estimates</th></tr><tr><th valign="top"/><th valign="top">Exposure</th><th valign="top"># SNPs</th><th valign="top">Method</th><th valign="top">OR</th><th valign="top">95% CI</th><th valign="top">P value</th><th valign="top">MR-Egger intercept p-value</th></tr></thead><tbody><tr><td valign="top">Men</td><td valign="top">Statin mimic</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">0.55</td><td valign="top">0.38 to 0.79</td><td valign="top">0.001</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Statin mimic</td><td valign="top">6</td><td valign="top">Inverse variance weighted</td><td valign="top">0.54</td><td valign="top">0.33 to 0.89</td><td valign="top">0.02</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">125</td><td valign="top">Inverse variance weighted</td><td valign="top">1.11</td><td valign="top">1.04 to 1.19</td><td valign="top">0.003</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">125</td><td valign="top">Weighted median</td><td valign="top">1.18</td><td valign="top">1.06 to 1.31</td><td valign="top">0.002</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">125</td><td valign="top">MR-Egger</td><td valign="top">1.10</td><td valign="top">0.98 to 1.23</td><td valign="top">0.09</td><td valign="top">0.01 (0.84)</td></tr><tr><td valign="top">Women</td><td valign="top">Statin mimic</td><td valign="top">1</td><td valign="top">Inverse variance weighted</td><td valign="top">0.87</td><td valign="top">0.59 to 1.27</td><td valign="top">0.46</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Statin mimic</td><td valign="top">6</td><td valign="top">Inverse variance weighted</td><td valign="top">0.79</td><td valign="top">0.54 to 1.13</td><td valign="top">0.20</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">254</td><td valign="top">Inverse variance weighted</td><td valign="top">0.96</td><td valign="top">0.89 to 1.03</td><td valign="top">0.29</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">254</td><td valign="top">Weighted median</td><td valign="top">1.03</td><td valign="top">0.92 to 1.14</td><td valign="top">0.63</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">254</td><td valign="top">MR-Egger</td><td valign="top">1.08</td><td valign="top">0.94 to 1.23</td><td valign="top">0.27</td><td valign="top">−0.004 (0.05)</td></tr></tbody></table><table-wrap-foot><fn><p>One statin SNP is rs12916, and six statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account all their correlations. The unit of LDL-cholesterol is approximately 0.83 mm/L. An effect size of testosterone is approximately, 0.23 nmol/L in women (<xref ref-type="bibr" rid="bib24">Haring et al., 2012</xref>) and 3.1 nmol/L in men (<xref ref-type="bibr" rid="bib39">Mohr et al., 2005</xref>).</p></fn></table-wrap-foot></table-wrap><p>Considering genetically mimicked effects of statin together with genetically predicted testosterone, in men the multivariable estimates for genetically mimicked effects of statins on IHD allowing for testosterone we attenuated (<xref ref-type="table" rid="table3">Table 3</xref>) compared to the univariable estimates for effects of statins on IHD (<xref ref-type="table" rid="table2">Table 2</xref>). As a result, the multivariable MR-Egger estimates for genetically mimicked effects of statins on IHD, allowing for testosterone, were very similar for men and women (odds ratio 0.72, 95% confidence interval 0.57 to 0.90 for men and women meta-analyzed together). The multivariable associations of genetically predicted testosterone with IHD in men and women, allowing for genetically mimicked statins, (<xref ref-type="table" rid="table3">Table 3</xref>) were very similar to the respective univariable estimates for men and women (<xref ref-type="table" rid="table2">Table 2</xref>), but differed by sex (z-test p-value 0.01). The conditional F-statistics were 58.2 (men) and 68.5 (women) for testosterone and 3.5 (men) and 6.8 (women) for effects of genetically mimicked statins. The Q statistics for instrument validity were significant (212.5 in men and 323.1 in women), and the multivariable MR-Egger intercepts were significant in men and women, substantiating the use of the MR-Egger estimates.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Multivariable Mendelian randomization estimates for effects of genetically mimicked statins (effect sizes of LDL-cholesterol) and of testosterone (effect size) together on IHD in men and women using the UK Biobank.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top"/><th valign="top"/><th valign="top"/><th valign="top"/><th colspan="3" valign="top">Mendelian randomization estimates</th><th valign="top"/></tr><tr><th valign="top">Sex</th><th valign="top">Exposures</th><th valign="top">Instrumented by</th><th valign="top">Adjusted for</th><th valign="top">Method</th><th valign="top">OR</th><th valign="top">95% CI</th><th valign="top">P value</th><th valign="top">MR-Egger intercept p-value</th></tr></thead><tbody><tr><td valign="top">Men</td><td valign="top">Statin mimic</td><td valign="top">1 Statin SNP on LDL-cholesterol</td><td valign="top">Testosterone</td><td valign="top">Inverse variance weighted</td><td valign="top">1.05</td><td valign="top">0.74 to 1.47</td><td valign="top">0.79</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">125 SNPs on testosterone</td><td valign="top">statin</td><td valign="top">Inverse variance weighted</td><td valign="top">1.11</td><td valign="top">1.04 to 1.20</td><td valign="top">0.003</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Statin mimic</td><td valign="top">1 Statin SNP on LDL-cholesterol</td><td valign="top">Testosterone</td><td valign="top">MR-Egger</td><td valign="top">0.73</td><td valign="top">0.48 to 1.11</td><td valign="top">0.14</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">125 SNPs on testosterone</td><td valign="top">statin</td><td valign="top">MR-Egger</td><td valign="top">1.09</td><td valign="top">1.02 to 1.17</td><td valign="top">0.02</td><td valign="top">0.005</td></tr><tr><td valign="top"/><td valign="top">Statin mimic</td><td valign="top">6 Statin SNPs on LDL-cholesterol</td><td valign="top">Testosterone</td><td valign="top">Inverse variance weighted</td><td valign="top">1.02</td><td valign="top">0.72 to 1.43</td><td valign="top">0.91</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">125 SNPs on testosterone</td><td valign="top">statin</td><td valign="top">Inverse variance weighted</td><td valign="top">1.11</td><td valign="top">1.04 to 1.20</td><td valign="top">0.003</td><td valign="top"/></tr><tr><td valign="top">Women</td><td valign="top">Statin mimic</td><td valign="top">1 Statin SNP on LDL-cholesterol</td><td valign="top">Testosterone</td><td valign="top">Inverse variance weighted</td><td valign="top">0.98</td><td valign="top">0.75 to 1.16</td><td valign="top">0.53</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">254 SNPs on testosterone</td><td valign="top">statin</td><td valign="top">Inverse variance weighted</td><td valign="top">0.96</td><td valign="top">0.90 to 1.04</td><td valign="top">0.33</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Statin mimic</td><td valign="top">1 Statin SNP on LDL-cholesterol</td><td valign="top">Testosterone</td><td valign="top">MR-Egger</td><td valign="top">0.72</td><td valign="top">0.55 to 0.94</td><td valign="top">0.02</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">254 SNPs on testosterone</td><td valign="top">statin</td><td valign="top">MR-Egger</td><td valign="top">0.96</td><td valign="top">0.89 to 1.03</td><td valign="top">0.27</td><td valign="top">0.001</td></tr><tr><td valign="top"/><td valign="top">Statin mimic</td><td valign="top">6 Statin SNPs on LDL-cholesterol</td><td valign="top">Testosterone</td><td valign="top">Inverse variance weighted</td><td valign="top">0.92</td><td valign="top">0.74 to 1.16</td><td valign="top">0.49</td><td valign="top"/></tr><tr><td valign="top"/><td valign="top">Testosterone</td><td valign="top">254 SNPs on testosterone</td><td valign="top">statin</td><td valign="top">Inverse variance weighted</td><td valign="top">0.97</td><td valign="top">0.90 to 1.04</td><td valign="top">0.36</td><td valign="top"/></tr></tbody></table><table-wrap-foot><fn><p>One statin SNP is rs12916, and six statin SNPs additionally included rs5909, rs10066707, rs17238484, rs2006760 and rs2303152 taking into account all their correlations. The unit of LDL-cholesterol is approximately 0.83 mm/L. An effect size of testosterone is approximately, 0.23 nmol/L in women (<xref ref-type="bibr" rid="bib24">Haring et al., 2012</xref>) and 3.1 nmol/L in men (<xref ref-type="bibr" rid="bib39">Mohr et al., 2005</xref>).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title>Sex-specific associations of genetically mimicked Anakinra and tocilizumab with testosterone and IHD</title><p>Genetically mimicked effects of anakinra increased both the risk of IHD and testosterone in men but not women (<xref ref-type="table" rid="table4">Table 4</xref>). Genetically mimicked effects of tocilizumab were not clearly associated with testosterone in men or women (<xref ref-type="table" rid="table4">Table 4</xref>), so were not investigated further. Investigation of whether testosterone mediates the genetically mimicked effect of anakinra on IHD was not possible because sex-specific genetic associations of testosterone SNPs with IL-1Ra from suitably large GWAS are not available.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Mendelian randomization inverse variance weighted estimates for genetically mimicked effects of the anti-inflammatory anakinra raising IL-1Ra (effect size) (<xref ref-type="bibr" rid="bib75">Swerdlow et al., 2012</xref>) on testosterone (effect size) and ischemic heart disease and for genetically mimicked effects of tocilizumab raising serum IL-6r (ng/ml) (<xref ref-type="bibr" rid="bib48">Rafiq et al., 2007</xref>) on testosterone in men and women using the UK Biobank .</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">Therapy</th><th valign="top">Target</th><th valign="top">Outcome</th><th valign="top"># SNPs</th><th valign="top">Measure</th><th valign="top">Estimate</th><th valign="top">95% CI</th><th valign="top">p-value</th></tr></thead><tbody><tr><td valign="top">Men</td><td valign="top">Anakinra</td><td valign="top">IL-1Ra</td><td valign="top">testosterone</td><td valign="top">2</td><td valign="top">beta</td><td valign="top">0.022</td><td valign="top">0.01 to 0.04</td><td valign="top">0.002</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">IHD</td><td valign="top">2</td><td valign="top">OR</td><td valign="top">1.08</td><td valign="top">1.01 to 1.15</td><td valign="top">0.017</td></tr><tr><td valign="top"/><td valign="top">Tocilizumab</td><td valign="top">IL-6r</td><td valign="top">testosterone</td><td valign="top">1</td><td valign="top">beta</td><td valign="top">0.003</td><td valign="top">−0.06 to 0.13</td><td valign="top">0.96</td></tr><tr><td valign="top">Women</td><td valign="top">Anakinra</td><td valign="top">IL-1Ra</td><td valign="top">testosterone</td><td valign="top">2</td><td valign="top">beta</td><td valign="top">−0.01</td><td valign="top">−0.04 to 0.01</td><td valign="top">0.24</td></tr><tr><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">IHD</td><td valign="top">2</td><td valign="top">OR</td><td valign="top">0.99</td><td valign="top">0.91 to 1.08</td><td valign="top">0.86</td></tr><tr><td valign="top"/><td valign="top">Tocilizumab</td><td valign="top">IL-6r</td><td valign="top">testosterone</td><td valign="top">1</td><td valign="top">beta</td><td valign="top">0.002</td><td valign="top">−0.02 to 0.02</td><td valign="top">0.84</td></tr></tbody></table><table-wrap-foot><fn><p>SNPs mimicking anakinra are rs6743376 and rs1542176.</p><p>The SNP mimicking tocilizumab is rs7529229.</p></fn><fn><p>An effect size of testosterone is approximately, 0.23 nmol/L in women (<xref ref-type="bibr" rid="bib24">Haring et al., 2012</xref>) and 3.1 nmol/L in men (<xref ref-type="bibr" rid="bib39">Mohr et al., 2005</xref>).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Consistent with meta-analysis of RCTs this study provides genetic evidence that statins reduce testosterone in men (<xref ref-type="bibr" rid="bib61">Schooling et al., 2013</xref>), and adds by showing that statins could partially operate on IHD, in men only, by reducing testosterone, as previously hypothesized (<xref ref-type="bibr" rid="bib61">Schooling et al., 2013</xref>; <xref ref-type="bibr" rid="bib62">Schooling et al., 2014</xref>) while having similar protective effects in men and women independent of testosterone. Previous Mendelian randomization studies have shown lower testosterone associated with lower risk of IHD, particularly in men (<xref ref-type="bibr" rid="bib65">Schooling et al., 2018a</xref>; <xref ref-type="bibr" rid="bib34">Luo et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Mohammadi-Shemirani et al., 2019</xref>). Conversely, consistent with an RCT (<xref ref-type="bibr" rid="bib16">Ebrahimi et al., 2018</xref>), this study also provides genetic validation that the anti-inflammatory anakinra, targeting IL-1Ra, increases testosterone in men, and is consistent with a previous Mendelian randomization study showing anakinra increases IHD (<xref ref-type="bibr" rid="bib27">Interleukin 1 Genetics Consortium, 2015</xref>), but adds by showing why these associations might occur and that they may be specific to men.</p><p>A more marked association of testosterone with IHD in men than women (<xref ref-type="table" rid="table2">Table 2</xref>) is consistent with sex differences in biology, where testosterone is the main sex hormone in men and is much higher in men than in women. The associations of genetically mimicked effects of statins, PCSK9 inhibitors or ezetimibe on testosterone is consistent with the evidence available (<xref ref-type="bibr" rid="bib61">Schooling et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Ooi et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Krysiak et al., 2015</xref>) and their mechanisms of action. Specifically, statins inhibit cholesterol synthesis, while PCSK9 inhibitors enable greater clearance of cholesterol, through increasing LDL-receptors, while ezetimibe reduces uptake of dietary cholesterol (<xref ref-type="bibr" rid="bib49">Ray et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">Michos et al., 2019</xref>). However, some cells, such as Leydig cells, use de novo cholesterol synthesis to generate steroids, which can be reduced by statins (<xref ref-type="bibr" rid="bib71">Shimizu-Albergine et al., 2016</xref>). Concerns about statins compromising androgen production pre-date the marketing of statins (<xref ref-type="bibr" rid="bib19">Farnsworth et al., 1987</xref>; <xref ref-type="bibr" rid="bib35">MacDonald et al., 1988</xref>). Beneficial immunosuppressive effects of androgens in rheumatoid arthritis have long been known (<xref ref-type="bibr" rid="bib15">Cutolo et al., 1991</xref>), making androgen reduction a plausible mode of action for therapies, such as anakinra, whose primary indication is rheumatoid arthritis.</p><p>These findings may seem counter-intuitive given the essential role of testosterone in masculinity and reproduction. However, in 2015 the Food and Drug Administration in the United States required labelling changes for all testosterone prescriptions to warn of the risk of heart attacks and stroke on testosterone, although no sufficiently large RCT of testosterone administration has been conducted to confirm these effects (<xref ref-type="bibr" rid="bib42">Onasanya et al., 2016</xref>). The Endocrine Society has also recommended caution in the use of testosterone (<xref ref-type="bibr" rid="bib6">Bhasin et al., 2018</xref>). Meta-analysis of RCTs suggests androgen deprivation therapy reduces all-cause mortality, but is too small to quantify effects on specific diseases beyond prostate cancer (<xref ref-type="bibr" rid="bib40">Nguyen et al., 2011</xref>). As such, our Mendelian randomization findings of the effects of testosterone have some consistency with the limited experimental evidence. In addition, our findings are consistent with well-established evolutionary biology theory, that is reproductive success may be at the expense of longevity, possibly in a sex-specific manner, impling that central drivers of the reproductive axis, as well as androgen production and catabolism, and their environmental cues may be relevant to IHD (<xref ref-type="bibr" rid="bib63">Schooling, 2016</xref>; <xref ref-type="bibr" rid="bib68">Schooling and Ng, 2019</xref>; <xref ref-type="fig" rid="fig2">Figure 2</xref>) encompassing the relations tested here (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Notably, upregulation of indicators of plentiful living conditions, such as insulin, appear to cause IHD, particularly in men (<xref ref-type="bibr" rid="bib84">Zhao et al., 2019</xref>), likely via gonadotropin releasing hormone (GnRH) (<xref ref-type="bibr" rid="bib68">Schooling and Ng, 2019</xref>). Similarly, fatty acids may affect GnRH (<xref ref-type="bibr" rid="bib78">Tran et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Matsuyama and Kimura, 2015</xref>). In contrast, indicators of adversity, such as endotoxins promote an inflammatory response, involving interleukins, which suppresses the reproductive axis (<xref ref-type="bibr" rid="bib28">Kalra et al., 1998</xref>) and thereby testosterone (<xref ref-type="bibr" rid="bib79">Tremellen et al., 2018</xref>), which may be reversed by anakinra possibly outweighing the benefits for IHD of suppressing inflammation (<xref ref-type="bibr" rid="bib77">Tardif et al., 2019</xref>). Statins, in contrast reduce androgen production, while agents that suppress androgen catabolism, such as rofecoxib, have also had unexpectedly adverse effects on IHD (<xref ref-type="bibr" rid="bib63">Schooling, 2016</xref>). Mechanisms by which androgens might cause IHD have not been extensively investigated, but likely involve coagulation and red blood cell attributes. Several haemostatic and thrombotic factors, such as thromboxane A<sub>2</sub> (<xref ref-type="bibr" rid="bib45">Pignatelli et al., 2012</xref>; <xref ref-type="bibr" rid="bib2">Ajayi and Halushka, 2005</xref>), endothelin-1 (<xref ref-type="bibr" rid="bib47">Polderman et al., 1993</xref>; <xref ref-type="bibr" rid="bib80">van Kesteren et al., 1998</xref>; <xref ref-type="bibr" rid="bib55">Sahebkar et al., 2015</xref>), nitric oxide (<xref ref-type="bibr" rid="bib45">Pignatelli et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Rosselli et al., 1998</xref>) and possibly thrombin (<xref ref-type="bibr" rid="bib44">Orsi et al., 2019</xref>; <xref ref-type="bibr" rid="bib21">Ferenchick et al., 1995</xref>), may be driven by androgens and likely play a role in IHD (<xref ref-type="bibr" rid="bib66">Schooling et al., 2018b</xref>; <xref ref-type="bibr" rid="bib83">Zhao, 2018</xref>; <xref ref-type="bibr" rid="bib41">Nikpay et al., 2015</xref>). Von Willebrand factor (<xref ref-type="bibr" rid="bib56">Sahebkar et al., 2016</xref>) and asymmetric dimethylarginine (<xref ref-type="bibr" rid="bib70">Serban et al., 2015</xref>) are also modulated by statins and may cause IHD (<xref ref-type="bibr" rid="bib1">Aday and Ridker, 2018</xref>; <xref ref-type="bibr" rid="bib5">Au Yeung et al., 2016</xref>), whether they are driven by testosterone is unknown. Several red blood cell attributes are affected by androgens, from reticulocytes to hematocrit (<xref ref-type="bibr" rid="bib22">Fernández-Balsells et al., 2010</xref>; <xref ref-type="bibr" rid="bib29">Kanias et al., 2016</xref>), but exactly which causes IHD is unclear, although reticulocytes are a possibility (<xref ref-type="bibr" rid="bib4">Astle et al., 2016</xref>). Currently, comprehensive genetic validation of these pathways is hampered by the lack of availability of large sex-specific genome wide association studies (GWAS) of cytokines and coagulation factors.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Schematic diagram showing the well-established protective effects of lipid modifiers on IHD (solid green lines) in the context of additional relevant pathways (green protective, red harmful) from an evolutionary biology perspective.</title><p>(Key: GnRH: gonadotropin releasing hormone, RBC: red blood cell, LDL: low density lipoprotein).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58567-fig2-v2.tif"/></fig><p>Despite providing information that may be relevant to the performance of statins, and to the development of other therapies to protect against cardiovascular disease (<xref ref-type="bibr" rid="bib64">Schooling, 2017</xref>), some limitations of this study exist. First, valid instruments should fulfill three assumptions, that is relate strongly to the exposure, not be associated with potential confounders and satisfy the exclusion restriction assumption. The F-statistics were &gt;10. Despite high conditional F-statistics for testosterone the conditional F-statistics for the genetic mimics of statins were quite low and the Q-statistics for instrument validity were high suggesting pleiotropy, which we addressed by using multivariable MR-Egger. The associations with testosterone in women were not adjusted for factors, such as menopausal status, hormone use and history of oophorectomy, which could result in imprecision and weaker instruments. The SNPs used to mimic effects of statins, PCSK9 inhibitors and ezetimibe are well established (<xref ref-type="bibr" rid="bib20">Ference et al., 2019</xref>), and in genes that harbor the target of each lipid modifier (<italic>HMGCR, PCSK9</italic> and <italic>NCP1L1</italic> respectively). We did not include body mass index (BMI) as a risk factor explaining the effect of statins on IHD, because statins increase BMI (<xref ref-type="bibr" rid="bib76">Swerdlow et al., 2015</xref>) and decrease the risk of IHD, so including them in the multivariable analysis may inflate the effect of mimicking statins on IHD, rather than explaining part of their effect on IHD. The SNPs mimicking effects of the anti-inflammatory anakinra have been validated as increasing IL-1Ra (<xref ref-type="bibr" rid="bib27">Interleukin 1 Genetics Consortium, 2015</xref>), and the SNP used to mimic effects of tocilizumab is well-established as affecting IL-6r (<xref ref-type="bibr" rid="bib75">Swerdlow et al., 2012</xref>). Testosterone’s effects on IHD in men could be via adiposity, insulin or LDL-cholesterol rather than via testosterone. However, consistent with a previous MR study, we found testosterone did not affect BMI in men (<xref ref-type="bibr" rid="bib17">Eriksson et al., 2017</xref>), we also found little evidence that testosterone in men affected LDL-cholesterol (data not shown). We could not test whether testosterone in men affects insulin because of the lack of an insulin GWAS including the X chromosome. Sex-specific genetic associations were used throughout with exception of the genetic mimics of effects of anakinra and tocilizumab on IL1Ra and IL-6r respectively. However, inflammation operating on the reproductive axis would be expected to have sex-specific effects not sex-specific drivers. We selected between correlated SNPs based on p-values which is relatively arbitrary, and the estimates could be sensitive to the choice of SNPs. Repeating the analysis using a larger number of correlated SNPs, where possible, taking into account their correlation, gave a similar interpretation. MR studies can be confounded by population stratification. However, we used genetic associations from GWAS mainly comprising people of white British ancestry with genomic control. Functions of each SNP predicting the exposures are not all fully understood, so we cannot rule out the possibility that the SNPs are linked with IHD through other pathways although we used sensitivity analysis.</p><p>We used SNPs predicting testosterone, but not other exposures, obtained from the same study as the genetic effects on IHD. However given the estimates for testosterone were largely obtained from non-cases, the overlap unlikely introduced substantial bias (<xref ref-type="bibr" rid="bib11">Burgess et al., 2016</xref>). Canalization, that is buffering of genetic factors during development, may occur however; whether it does so is unknown. Our findings, largely in Europeans, may not be applicable to other populations. However, causes are unlikely to act differently in different populations, although the causal mechanisms may not be as relevant in all settings (<xref ref-type="bibr" rid="bib33">Lopez et al., 2019</xref>). The SNPs mimicking effects of statins, PCSK9 inhibitors and ezetimibe were previously selected for their relations with LDL-cholesterol and on functional grounds (<xref ref-type="bibr" rid="bib20">Ference et al., 2019</xref>), assuming the lipid modifiers act by action on lipids (<xref ref-type="bibr" rid="bib20">Ference et al., 2019</xref>), so it is possible that relevant SNPs might have been discarded if they work through other mechanisms independent of lipids. It is also possible that the SNPs mimicking lipid modifiers might act via a different lipid trait, such as apoB (<xref ref-type="bibr" rid="bib51">Richardson et al., 2020</xref>). The SNPs mimicking effects of anakinra and tocilizumab were similarly selected. Replication based on genetic instruments functionally relevant to all the exposures would be ideal. However, we used the most recent, published genetic instruments for testosterone (<xref ref-type="bibr" rid="bib54">Ruth et al., 2020</xref>). Replication based on another large sex-specific IHD GWAS where the IHD cases are not from the same study as the testosterone instruments, would be ideal. However, sex-specific summary statistics are not available for large existing IHD GWAS, such as CARDIoGRAM (<xref ref-type="bibr" rid="bib41">Nikpay et al., 2015</xref>). Moreover, the UK Biobank has the advantage of being very intensively genotyped and including the X chromosome, which is important for testosterone, but is not usually included in publicly available summary statistics. Lack of replication is a limitation of this study. Lastly, Mendelian randomization assesses the lifelong effects of an endogenous exposure rather than short-term effects of an interventions assessed in an RCT. Our estimates give an indication of the role of the exposures rather than the exact effects of the corresponding interventions. Nevertheless our estimates for statins on IHD are comparable with meta-analyses of statin trials considering similar outcomes (<xref ref-type="bibr" rid="bib23">Fulcher et al., 2015</xref>).</p><p>Here, we present a hypothesis driven study examining the role of testosterone in mediating the effect of specifically statins in IHD, particularly in men. Future work could encompass a comprehensive sex-specific multivariable MR to confirm the role of sex hormones and sex hormone binding globulin in IHD as well as any mediation of their effects by key lipids, such as LDL-cholesterol or apoB. This work would be facilitated by the development of published genetic instruments for estrogen in women. Future work could also encompass assessing whether any other drugs that reduce cardiovascular disease, such as canakinumab (<xref ref-type="bibr" rid="bib52">Ridker et al., 2017</xref>), also impact testosterone.</p><p>Taken together these complimentary findings for statins and anakinra raise the possibility that modulating testosterone, by whatever means, is a relevant feature for modulating IHD in men, with potential relevance to the development of new interventions, side-effects of existing interventions, re-purposing and appropriate use. Statins lowering testosterone could also be relevant to the muscle weakness or pain experienced on statins (<xref ref-type="bibr" rid="bib14">Collins et al., 2016</xref>). Recognition that statins lower testosterone might also provide greater impetus for investigation of their role in other relevant conditions, such as prostate cancer (<xref ref-type="bibr" rid="bib3">Alfaqih et al., 2017</xref>). Conversely, statins and anakinra did not clearly affect testosterone in women (<xref ref-type="table" rid="table1">Table 1</xref>) nor did testosterone mediate the effect of statins on IHD in women (<xref ref-type="table" rid="table3">Table 3</xref>). These differences by sex highlight the need for sex-specific approaches to IHD prevention and management, specifically in terms of the use of statins and investigation more broadly of causes of IHD.</p><sec id="s3-1"><title>Conclusion</title><p>Genetic variants mimicking effects of statins and anakinra had opposite effects on testosterone and IHD in men, consistent with the effects of statins on IHD in men being partially mediated by testosterone. This insight that the pleiotropic effects of statins could be mediated by testosterone in men has implications for the use of existing interventions to prevent and treat IHD, the development of new interventions for IHD and the re-use of statins for other androgen related conditions. Genetic confirmation that anakinra raises testosterone suggests its use in rheumatoid arthritis might have cardiovascular side-effects, particularly in men. It also highlights the importance of considering whether vulnerability to major diseases and interventions to promote lifespan need to be sex-specific.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Genetic predictors mimicking effects of lipid and interleukin modifiers</title><p>Established genetic variants mimicking effects of statins, PCSK9 inhibitors and ezetimibe were taken from published sources (<xref ref-type="bibr" rid="bib20">Ference et al., 2019</xref>) which selected SNPs from genes encoding proteins of the targets of each lipid modifier (<italic>HMGCR</italic> for statins, <italic>PCSK9</italic> for PCSK9 inhibitors and <italic>NCP1L1</italic> for ezetimibe) that lowered LDL-cholesterol. Genetic effects mimicking statins, PCSK9 inhibitors and ezetimibe were expressed in sex-specific effect sizes of LDL-cholesterol reduction taken from the largest available sex-specific GWAS summary statistics, that is the UK Biobank (<ext-link ext-link-type="uri" xlink:href="http://www.nealelab.is/uk-biobank">http://www.nealelab.is/uk-biobank</ext-link>). The study was restricted to people of white British ancestry adjusted for the first 20 principal components, age, and age<sup>2</sup>. In the main analysis for each lipid modifier, we only used independent (r<sup>2</sup> &lt;0.05) SNPs most strongly associated with LDL-cholesterol. We obtained correlations between SNPs for each lipid modifier based on the 1000 Genomes catalog from LDlink (<ext-link ext-link-type="uri" xlink:href="https://ldlink.nci.nih.gov">https://ldlink.nci.nih.gov</ext-link>). In sensitivity analysis, we used all the relevant SNPs for each lipid modifier, along with a matrix of their correlations. Established genetic variants mimicking effects of anakinra and tocilizumab and their effects on IL-1Ra and IL-6r respectively were also taken from published sources (<xref ref-type="bibr" rid="bib75">Swerdlow et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Rafiq et al., 2007</xref>).</p></sec><sec id="s4-2"><title>Sex-specific genetic predictors of testosterone</title><p>Strong (p-value&lt;5 × 10<sup>−8</sup>), independent (r<sup>2</sup> &lt;0.05), sex-specific genetic predictors of testosterone were extracted from a published genome wide association study (GWAS) based on the UK Biobank and replicated in three independent studies (CHARGE Consortium, Twins UK and EPIC-Norfolk) (<xref ref-type="bibr" rid="bib54">Ruth et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Sinnott-Armstrong et al., 2019</xref>). Genetic associations with testosterone in this study were adjusted for genotyping chip/release of genetic data, age at baseline, fasting time and ten genetically derived principal components (<xref ref-type="bibr" rid="bib54">Ruth et al., 2020</xref>). We used all 125 genetic variants given for bioavailable testosterone, hereafter testosterone, in men and all 254 genetic variants given for testosterone in women, as previously (<xref ref-type="bibr" rid="bib85">Zhao and Schooling, 2020</xref>), because these had little correlation with sex hormone binding globulin (0.05 in men and 0.06 in women) (<xref ref-type="bibr" rid="bib54">Ruth et al., 2020</xref>).</p></sec><sec id="s4-3"><title>Sex-specific genetic associations with IHD</title><p>Sex-specific genetic associations with IHD were taken from the UK Biobank individual data after excluding those with inconsistent self-reported and genotyped sex, excess relatedness (more than 10 putative third-degree relatives), abnormal sex chromosomes (such as XXY), or poor-quality genotyping (heterozygosity or missing rate &gt;1.5%). The sex-specific associations with IHD obtained using logistic regression were adjusted for the first 20 principal components, age, and assay array. IHD was based on self-report at baseline, subsequent hospitalization diagnoses (primary or secondary) of International Classification of Diseases (ICD) 9 410–4 or ICD10 I20-5 and death registration causes (primary or secondary) of ICD10 I20-5 up until December 2019.</p></sec><sec id="s4-4"><title>Statistical analysis</title><p>The F-statistic was used to assess instrument strength, obtained using an approximation (mean of square of SNP-exposure association divided by square of its standard error) (<xref ref-type="bibr" rid="bib8">Bowden et al., 2016a</xref>). A conventional threshold for the F-statistic is 10. SNPs with an F-statistic &lt;10 were dropped.</p><p>Steiger filtering was used to check the directionality between testosterone and IHD. (<xref ref-type="bibr" rid="bib25">Hemani et al., 2017</xref>) Sex-specific estimates of the associations of genetically predicted exposures (i.e., genetically mimicked effects of statins, PCSK9 inhibitors, ezetimibe, anakinra and tocilizumab) with testosterone and IHD, as well as estimates of the associations of genetically predicted testosterone with IHD were obtained by combining SNP-specific Wald estimates (SNP on outcome divided by SNP on exposure) using inverse variance weighting (IVW) with multiplicative random effects (<xref ref-type="bibr" rid="bib10">Burgess et al., 2013</xref>). Multivariable MR was used to assess sex-specific associations of genetically predicted exposures with IHD allowing for testosterone, accounting for correlations between SNPs on the same chromosome obtained from LDlink. In the multivariable MR, we pooled the genetic instruments mimicking statins and the genetic instruments for testosterone together, extracted their associations with LDL-cholesterol and testosterone and fitted one multivariable model. We estimated the Sanderson-Windmejier multivariable conditional F-statistic (<xref ref-type="bibr" rid="bib58">Sanderson and Windmeijer, 2016</xref>) to obtain a lower bound of the strength for each instrument conditional on the other exposure, and the Q statistics to asses pleiotropy, using the WSpiller/MVMR package (<xref ref-type="bibr" rid="bib57">Sanderson et al., 2019</xref>). Given this analysis is multivariable by design with few genetic variants available to mimic the effects of statins, we used the multivariable MR-Egger estimates (<xref ref-type="bibr" rid="bib50">Rees et al., 2017</xref>).</p></sec><sec id="s4-5"><title>Sensitivity analysis</title><p>Where possible we used methods with different assumptions to assess the validity of the univariable MR estimates from IVW, which assumes balanced pleiotropy. MR-Egger is valid as long as the instrument strength independent of direct effect assumption holds (<xref ref-type="bibr" rid="bib7">Bowden et al., 2015</xref>). We also used a weighted median which gives valid estimates when more than 50% of information comes from valid SNPs (<xref ref-type="bibr" rid="bib9">Bowden et al., 2016b</xref>). However, for exposures instrumented by correlated SNPs we did not give the weighted median or MR-Egger estimates because of concerns about their interpretability (<xref ref-type="bibr" rid="bib12">Burgess and Thompson, 2017</xref>).</p><p>Given this is a hypothesis driven study, with a positive control, we used a statistical significance level of 0.05. All statistical analysis was conducted using R version 3.6.1 (The R Foundation for Statistical Computing, Vienna, Austria). The MendelianRandomization R package was used for the MR estimates. Estimates of genetic associations were taken from publicly available UK Biobank summary statistics, except the associations with IHD which were based on individual level genetic associations from the UK Biobank obtained under application #42468. All UK Biobank data were collected with fully informed consent.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p><bold>Funding:</bold> This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Supervision, Validation, Methodology, Writing - original draft, Project administration</p></fn><fn fn-type="con" id="con2"><p>Data curation, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation, Supervision, Investigation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Methodology, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: This study is analysis of summary data previously collected with full consent.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Associations of SNPs mimicking effects of lipid modifiers with LDL-cholesterol.</title><p>(a) SNP-specific estimates for SNPs mimicking effects of statins, PCSK9 inhibitor and ezetimibe on LDL-cholesterol (effect size) in women and men from the UK Biobank, and for comparison estimates for both sexes together from the <italic>Global Lipids</italic> Genetics <italic>Consortium</italic> (GLGC) (<xref ref-type="bibr" rid="bib81">Willer et al., 2013</xref>). (b) SNP-specific estimates for anakinra and tocilizumab SNPs on IL1-Ra (<xref ref-type="bibr" rid="bib27">Interleukin 1 Genetics Consortium, 2015</xref>) and IL-6 (<xref ref-type="bibr" rid="bib75">Swerdlow et al., 2012</xref>) respectively.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-58567-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-58567-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aday</surname> <given-names>AW</given-names></name><name><surname>Ridker</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antiinflammatory therapy in clinical care: the CANTOS trial and beyond</article-title><source>Frontiers in Cardiovascular Medicine</source><volume>5</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2018.00062</pub-id><pub-id pub-id-type="pmid">29922680</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajayi</surname> <given-names>AAL</given-names></name><name><surname>Halushka</surname> <given-names>PV</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Castration reduces platelet thromboxane A2 receptor density and aggregability</article-title><source>QJM: An International Journal of Medicine</source><volume>98</volume><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hci054</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfaqih</surname> <given-names>MA</given-names></name><name><surname>Allott</surname> <given-names>EH</given-names></name><name><surname>Hamilton</surname> <given-names>RJ</given-names></name><name><surname>Freeman</surname> <given-names>MR</given-names></name><name><surname>Freedland</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The current evidence on statin use and prostate Cancer prevention: are we there yet?</article-title><source>Nature Reviews Urology</source><volume>14</volume><fpage>107</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2016.199</pub-id><pub-id pub-id-type="pmid">27779230</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astle</surname> <given-names>WJ</given-names></name><name><surname>Elding</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>T</given-names></name><name><surname>Allen</surname> <given-names>D</given-names></name><name><surname>Ruklisa</surname> <given-names>D</given-names></name><name><surname>Mann</surname> <given-names>AL</given-names></name><name><surname>Mead</surname> <given-names>D</given-names></name><name><surname>Bouman</surname> <given-names>H</given-names></name><name><surname>Riveros-Mckay</surname> <given-names>F</given-names></name><name><surname>Kostadima</surname> <given-names>MA</given-names></name><name><surname>Lambourne</surname> <given-names>JJ</given-names></name><name><surname>Sivapalaratnam</surname> <given-names>S</given-names></name><name><surname>Downes</surname> <given-names>K</given-names></name><name><surname>Kundu</surname> <given-names>K</given-names></name><name><surname>Bomba</surname> <given-names>L</given-names></name><name><surname>Berentsen</surname> <given-names>K</given-names></name><name><surname>Bradley</surname> <given-names>JR</given-names></name><name><surname>Daugherty</surname> <given-names>LC</given-names></name><name><surname>Delaneau</surname> <given-names>O</given-names></name><name><surname>Freson</surname> <given-names>K</given-names></name><name><surname>Garner</surname> <given-names>SF</given-names></name><name><surname>Grassi</surname> <given-names>L</given-names></name><name><surname>Guerrero</surname> <given-names>J</given-names></name><name><surname>Haimel</surname> <given-names>M</given-names></name><name><surname>Janssen-Megens</surname> <given-names>EM</given-names></name><name><surname>Kaan</surname> <given-names>A</given-names></name><name><surname>Kamat</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>B</given-names></name><name><surname>Mandoli</surname> <given-names>A</given-names></name><name><surname>Marchini</surname> <given-names>J</given-names></name><name><surname>Martens</surname> <given-names>JHA</given-names></name><name><surname>Meacham</surname> <given-names>S</given-names></name><name><surname>Megy</surname> <given-names>K</given-names></name><name><surname>O’Connell</surname> <given-names>J</given-names></name><name><surname>Petersen</surname> <given-names>R</given-names></name><name><surname>Sharifi</surname> <given-names>N</given-names></name><name><surname>Sheard</surname> <given-names>SM</given-names></name><name><surname>Staley</surname> <given-names>JR</given-names></name><name><surname>Tuna</surname> <given-names>S</given-names></name><name><surname>van der Ent</surname> <given-names>M</given-names></name><name><surname>Walter</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>S-Y</given-names></name><name><surname>Wheeler</surname> <given-names>E</given-names></name><name><surname>Wilder</surname> <given-names>SP</given-names></name><name><surname>Iotchkova</surname> <given-names>V</given-names></name><name><surname>Moore</surname> <given-names>C</given-names></name><name><surname>Sambrook</surname> <given-names>J</given-names></name><name><surname>Stunnenberg</surname> <given-names>HG</given-names></name><name><surname>Di Angelantonio</surname> <given-names>E</given-names></name><name><surname>Kaptoge</surname> <given-names>S</given-names></name><name><surname>Kuijpers</surname> <given-names>TW</given-names></name><name><surname>Carrillo-de-Santa-Pau</surname> <given-names>E</given-names></name><name><surname>Juan</surname> <given-names>D</given-names></name><name><surname>Rico</surname> <given-names>D</given-names></name><name><surname>Valencia</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Ge</surname> <given-names>B</given-names></name><name><surname>Vasquez</surname> <given-names>L</given-names></name><name><surname>Kwan</surname> <given-names>T</given-names></name><name><surname>Garrido-Martín</surname> <given-names>D</given-names></name><name><surname>Watt</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Guigo</surname> <given-names>R</given-names></name><name><surname>Beck</surname> <given-names>S</given-names></name><name><surname>Paul</surname> <given-names>DS</given-names></name><name><surname>Pastinen</surname> <given-names>T</given-names></name><name><surname>Bujold</surname> <given-names>D</given-names></name><name><surname>Bourque</surname> <given-names>G</given-names></name><name><surname>Frontini</surname> <given-names>M</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Roberts</surname> <given-names>DJ</given-names></name><name><surname>Ouwehand</surname> <given-names>WH</given-names></name><name><surname>Butterworth</surname> <given-names>AS</given-names></name><name><surname>Soranzo</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The allelic landscape of human blood cell trait variation and links to common complex disease</article-title><source>Cell</source><volume>167</volume><fpage>1415</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.10.042</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au Yeung</surname> <given-names>SL</given-names></name><name><surname>Lin</surname> <given-names>SL</given-names></name><name><surname>Lam</surname> <given-names>HS</given-names></name><name><surname>Schooling</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Effect of l-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine on ischemic heart disease risk: a mendelian randomization study</article-title><source>American Heart Journal</source><volume>182</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2016.07.021</pub-id><pub-id pub-id-type="pmid">27914500</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhasin</surname> <given-names>S</given-names></name><name><surname>Brito</surname> <given-names>JP</given-names></name><name><surname>Cunningham</surname> <given-names>GR</given-names></name><name><surname>Hayes</surname> <given-names>FJ</given-names></name><name><surname>Hodis</surname> <given-names>HN</given-names></name><name><surname>Matsumoto</surname> <given-names>AM</given-names></name><name><surname>Snyder</surname> <given-names>PJ</given-names></name><name><surname>Swerdloff</surname> <given-names>RS</given-names></name><name><surname>Wu</surname> <given-names>FC</given-names></name><name><surname>Yialamas</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline</article-title><source>The Journal of Clinical Endocrinology &amp; Metabolism</source><volume>103</volume><fpage>1715</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1210/jc.2018-00229</pub-id><pub-id pub-id-type="pmid">29562364</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowden</surname> <given-names>J</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mendelian randomization with invalid instruments: effect estimation and Bias detection through egger regression</article-title><source>International Journal of Epidemiology</source><volume>44</volume><fpage>512</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1093/ije/dyv080</pub-id><pub-id pub-id-type="pmid">26050253</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowden</surname> <given-names>J</given-names></name><name><surname>Del Greco M</surname> <given-names>F</given-names></name><name><surname>Minelli</surname> <given-names>C</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Sheehan</surname> <given-names>NA</given-names></name><name><surname>Thompson</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic</article-title><source>International Journal of Epidemiology</source><volume>45</volume><fpage>1961</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.1093/ije/dyw220</pub-id><pub-id pub-id-type="pmid">27616674</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowden</surname> <given-names>J</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Haycock</surname> <given-names>PC</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator</article-title><source>Genetic Epidemiology</source><volume>40</volume><fpage>304</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1002/gepi.21965</pub-id><pub-id pub-id-type="pmid">27061298</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Butterworth</surname> <given-names>A</given-names></name><name><surname>Thompson</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mendelian randomization analysis with multiple genetic variants using summarized data</article-title><source>Genetic Epidemiology</source><volume>37</volume><fpage>658</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1002/gepi.21758</pub-id><pub-id pub-id-type="pmid">24114802</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Davies</surname> <given-names>NM</given-names></name><name><surname>Thompson</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bias due to participant overlap in two-sample mendelian randomization</article-title><source>Genetic Epidemiology</source><volume>40</volume><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1002/gepi.21998</pub-id><pub-id pub-id-type="pmid">27625185</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Thompson</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interpreting findings from mendelian randomization using the MR-Egger method</article-title><source>European Journal of Epidemiology</source><volume>32</volume><fpage>377</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1007/s10654-017-0255-x</pub-id><pub-id pub-id-type="pmid">28527048</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>What makes UK biobank special?</article-title><source>The Lancet</source><volume>379</volume><fpage>1173</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60404-8</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname> <given-names>R</given-names></name><name><surname>Reith</surname> <given-names>C</given-names></name><name><surname>Emberson</surname> <given-names>J</given-names></name><name><surname>Armitage</surname> <given-names>J</given-names></name><name><surname>Baigent</surname> <given-names>C</given-names></name><name><surname>Blackwell</surname> <given-names>L</given-names></name><name><surname>Blumenthal</surname> <given-names>R</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>DeMets</surname> <given-names>D</given-names></name><name><surname>Evans</surname> <given-names>S</given-names></name><name><surname>Law</surname> <given-names>M</given-names></name><name><surname>MacMahon</surname> <given-names>S</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Neal</surname> <given-names>B</given-names></name><name><surname>Poulter</surname> <given-names>N</given-names></name><name><surname>Preiss</surname> <given-names>D</given-names></name><name><surname>Ridker</surname> <given-names>P</given-names></name><name><surname>Roberts</surname> <given-names>I</given-names></name><name><surname>Rodgers</surname> <given-names>A</given-names></name><name><surname>Sandercock</surname> <given-names>P</given-names></name><name><surname>Schulz</surname> <given-names>K</given-names></name><name><surname>Sever</surname> <given-names>P</given-names></name><name><surname>Simes</surname> <given-names>J</given-names></name><name><surname>Smeeth</surname> <given-names>L</given-names></name><name><surname>Wald</surname> <given-names>N</given-names></name><name><surname>Yusuf</surname> <given-names>S</given-names></name><name><surname>Peto</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Interpretation of the evidence for the efficacy and safety of statin therapy</article-title><source>The Lancet</source><volume>388</volume><fpage>2532</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31357-5</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutolo</surname> <given-names>M</given-names></name><name><surname>Balleari</surname> <given-names>E</given-names></name><name><surname>Giusti</surname> <given-names>M</given-names></name><name><surname>Intra</surname> <given-names>E</given-names></name><name><surname>Accardo</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Androgen replacement therapy in male patients with rheumatoid arthritis</article-title><source>Arthritis &amp; Rheumatism</source><volume>34</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1002/art.1780340102</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahimi</surname> <given-names>F</given-names></name><name><surname>Urwyler</surname> <given-names>SA</given-names></name><name><surname>Straumann</surname> <given-names>S</given-names></name><name><surname>Doerpfeld</surname> <given-names>S</given-names></name><name><surname>Bernasconi</surname> <given-names>L</given-names></name><name><surname>Neyer</surname> <given-names>P</given-names></name><name><surname>Schuetz</surname> <given-names>P</given-names></name><name><surname>Mueller</surname> <given-names>B</given-names></name><name><surname>Donath</surname> <given-names>MY</given-names></name><name><surname>Christ-Crain</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IL-1 antagonism in men with metabolic syndrome and low testosterone: a randomized clinical trial</article-title><source>The Journal of Clinical Endocrinology &amp; Metabolism</source><volume>103</volume><fpage>3466</fpage><lpage>3476</lpage><pub-id pub-id-type="doi">10.1210/jc.2018-00739</pub-id><pub-id pub-id-type="pmid">29939279</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname> <given-names>J</given-names></name><name><surname>Haring</surname> <given-names>R</given-names></name><name><surname>Grarup</surname> <given-names>N</given-names></name><name><surname>Vandenput</surname> <given-names>L</given-names></name><name><surname>Wallaschofski</surname> <given-names>H</given-names></name><name><surname>Lorentzen</surname> <given-names>E</given-names></name><name><surname>Hansen</surname> <given-names>T</given-names></name><name><surname>Mellström</surname> <given-names>D</given-names></name><name><surname>Pedersen</surname> <given-names>O</given-names></name><name><surname>Nauck</surname> <given-names>M</given-names></name><name><surname>Lorentzon</surname> <given-names>M</given-names></name><name><surname>Nystrup Husemoen</surname> <given-names>LL</given-names></name><name><surname>Völzke</surname> <given-names>H</given-names></name><name><surname>Karlsson</surname> <given-names>M</given-names></name><name><surname>Baumeister</surname> <given-names>SE</given-names></name><name><surname>Linneberg</surname> <given-names>A</given-names></name><name><surname>Ohlsson</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Causal relationship between obesity and serum testosterone status in men: a bi-directional mendelian randomization analysis</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0176277</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0176277</pub-id><pub-id pub-id-type="pmid">28448539</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezzati</surname> <given-names>M</given-names></name><name><surname>Obermeyer</surname> <given-names>Z</given-names></name><name><surname>Tzoulaki</surname> <given-names>I</given-names></name><name><surname>Mayosi</surname> <given-names>BM</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Leon</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Contributions of risk factors and medical care to cardiovascular mortality trends</article-title><source>Nature Reviews Cardiology</source><volume>12</volume><fpage>508</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2015.82</pub-id><pub-id pub-id-type="pmid">26076950</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farnsworth</surname> <given-names>WH</given-names></name><name><surname>Hoeg</surname> <given-names>JM</given-names></name><name><surname>Maher</surname> <given-names>M</given-names></name><name><surname>Brittain</surname> <given-names>EH</given-names></name><name><surname>Sherins</surname> <given-names>RJ</given-names></name><name><surname>Brewer</surname> <given-names>HB</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin</article-title><source>The Journal of Clinical Endocrinology &amp; Metabolism</source><volume>65</volume><fpage>546</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1210/jcem-65-3-546</pub-id><pub-id pub-id-type="pmid">3114306</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ference</surname> <given-names>BA</given-names></name><name><surname>Ray</surname> <given-names>KK</given-names></name><name><surname>Catapano</surname> <given-names>AL</given-names></name><name><surname>Ference</surname> <given-names>TB</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Neff</surname> <given-names>DR</given-names></name><name><surname>Oliver-Williams</surname> <given-names>C</given-names></name><name><surname>Wood</surname> <given-names>AM</given-names></name><name><surname>Butterworth</surname> <given-names>AS</given-names></name><name><surname>Di Angelantonio</surname> <given-names>E</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Kastelein</surname> <given-names>JJP</given-names></name><name><surname>Nicholls</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mendelian randomization study of <italic>ACLY</italic> and Cardiovascular Disease</article-title><source>New England Journal of Medicine</source><volume>380</volume><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1806747</pub-id><pub-id pub-id-type="pmid">30865797</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferenchick</surname> <given-names>GS</given-names></name><name><surname>Hirokawa</surname> <given-names>S</given-names></name><name><surname>Mammen</surname> <given-names>EF</given-names></name><name><surname>Schwartz</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system</article-title><source>American Journal of Hematology</source><volume>49</volume><fpage>282</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1002/ajh.2830490405</pub-id><pub-id pub-id-type="pmid">7639272</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Balsells</surname> <given-names>MM</given-names></name><name><surname>Murad</surname> <given-names>MH</given-names></name><name><surname>Lane</surname> <given-names>M</given-names></name><name><surname>Lampropulos</surname> <given-names>JF</given-names></name><name><surname>Albuquerque</surname> <given-names>F</given-names></name><name><surname>Mullan</surname> <given-names>RJ</given-names></name><name><surname>Agrwal</surname> <given-names>N</given-names></name><name><surname>Elamin</surname> <given-names>MB</given-names></name><name><surname>Gallegos-Orozco</surname> <given-names>JF</given-names></name><name><surname>Wang</surname> <given-names>AT</given-names></name><name><surname>Erwin</surname> <given-names>PJ</given-names></name><name><surname>Bhasin</surname> <given-names>S</given-names></name><name><surname>Montori</surname> <given-names>VM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis</article-title><source>The Journal of Clinical Endocrinology &amp; Metabolism</source><volume>95</volume><fpage>2560</fpage><lpage>2575</lpage><pub-id pub-id-type="doi">10.1210/jc.2009-2575</pub-id><pub-id pub-id-type="pmid">20525906</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulcher</surname> <given-names>J</given-names></name><name><surname>O'Connell</surname> <given-names>R</given-names></name><name><surname>Voysey</surname> <given-names>M</given-names></name><name><surname>Emberson</surname> <given-names>J</given-names></name><name><surname>Blackwell</surname> <given-names>L</given-names></name><name><surname>Mihaylova</surname> <given-names>B</given-names></name><name><surname>Simes</surname> <given-names>J</given-names></name><name><surname>Collins</surname> <given-names>R</given-names></name><name><surname>Kirby</surname> <given-names>A</given-names></name><name><surname>Colhoun</surname> <given-names>H</given-names></name><name><surname>Braunwald</surname> <given-names>E</given-names></name><name><surname>La Rosa</surname> <given-names>J</given-names></name><name><surname>Pedersen</surname> <given-names>TR</given-names></name><name><surname>Tonkin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>B</given-names></name><name><surname>Sleight</surname> <given-names>P</given-names></name><name><surname>Franzosi</surname> <given-names>MG</given-names></name><name><surname>Baigent</surname> <given-names>C</given-names></name><name><surname>Keech</surname> <given-names>A</given-names></name><collab>Cholesterol Treatment Trialists' (CTT) Collaboration</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials</article-title><source>Lancet</source><volume>385</volume><fpage>1397</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61368-4</pub-id><pub-id pub-id-type="pmid">25579834</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haring</surname> <given-names>R</given-names></name><name><surname>Hannemann</surname> <given-names>A</given-names></name><name><surname>John</surname> <given-names>U</given-names></name><name><surname>Radke</surname> <given-names>D</given-names></name><name><surname>Nauck</surname> <given-names>M</given-names></name><name><surname>Wallaschofski</surname> <given-names>H</given-names></name><name><surname>Owen</surname> <given-names>L</given-names></name><name><surname>Adaway</surname> <given-names>J</given-names></name><name><surname>Keevil</surname> <given-names>BG</given-names></name><name><surname>Brabant</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry</article-title><source>The Journal of Clinical Endocrinology &amp; Metabolism</source><volume>97</volume><fpage>408</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1210/jc.2011-2134</pub-id><pub-id pub-id-type="pmid">22162468</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemani</surname> <given-names>G</given-names></name><name><surname>Tilling</surname> <given-names>K</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Orienting the causal relationship between imprecisely measured traits using GWAS summary data</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1007081</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007081</pub-id><pub-id pub-id-type="pmid">29149188</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobbs</surname> <given-names>FD</given-names></name><name><surname>Banach</surname> <given-names>M</given-names></name><name><surname>Mikhailidis</surname> <given-names>DP</given-names></name><name><surname>Malhotra</surname> <given-names>A</given-names></name><name><surname>Capewell</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate</article-title><source>BMC Medicine</source><volume>14</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-016-0550-5</pub-id><pub-id pub-id-type="pmid">26769594</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Interleukin 1 Genetics Consortium</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a mendelian randomisation analysis</article-title><source>The Lancet Diabetes &amp; Endocrinology</source><volume>3</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(15)00034-0</pub-id><pub-id pub-id-type="pmid">25726324</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalra</surname> <given-names>PS</given-names></name><name><surname>Edwards</surname> <given-names>TG</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Jain</surname> <given-names>M</given-names></name><name><surname>Kalra</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The anti-gonadotropic effects of cytokines: the role of neuropeptides</article-title><source>Domestic Animal Endocrinology</source><volume>15</volume><fpage>321</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/S0739-7240(98)00030-7</pub-id><pub-id pub-id-type="pmid">9785036</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanias</surname> <given-names>T</given-names></name><name><surname>Sinchar</surname> <given-names>D</given-names></name><name><surname>Osei-Hwedieh</surname> <given-names>D</given-names></name><name><surname>Baust</surname> <given-names>JJ</given-names></name><name><surname>Jordan</surname> <given-names>A</given-names></name><name><surname>Zimring</surname> <given-names>JC</given-names></name><name><surname>Waterman</surname> <given-names>HR</given-names></name><name><surname>de Wolski</surname> <given-names>KS</given-names></name><name><surname>Acker</surname> <given-names>JP</given-names></name><name><surname>Gladwin</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Testosterone-dependent sex differences in red blood cell hemolysis in storage, stress, and disease</article-title><source>Transfusion</source><volume>56</volume><fpage>2571</fpage><lpage>2583</lpage><pub-id pub-id-type="doi">10.1111/trf.13745</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesteloot</surname> <given-names>H</given-names></name><name><surname>Decramer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Age at death from different diseases: the flemish experience during the period 2000-2004</article-title><source>Acta Clinica Belgica</source><volume>63</volume><fpage>256</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1179/acb.2008.047</pub-id><pub-id pub-id-type="pmid">19048704</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>SU</given-names></name><name><surname>Talluri</surname> <given-names>S</given-names></name><name><surname>Riaz</surname> <given-names>H</given-names></name><name><surname>Rahman</surname> <given-names>H</given-names></name><name><surname>Nasir</surname> <given-names>F</given-names></name><name><surname>Bin Riaz</surname> <given-names>I</given-names></name><name><surname>Sattur</surname> <given-names>S</given-names></name><name><surname>Ahmed</surname> <given-names>H</given-names></name><name><surname>Kaluski</surname> <given-names>E</given-names></name><name><surname>Krasuski</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes</article-title><source>European Journal of Preventive Cardiology</source><volume>25</volume><fpage>844</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1177/2047487318766612</pub-id><pub-id pub-id-type="pmid">29569492</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krysiak</surname> <given-names>R</given-names></name><name><surname>Kowalska</surname> <given-names>B</given-names></name><name><surname>Żmuda</surname> <given-names>W</given-names></name><name><surname>Okopień</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels</article-title><source>Pharmacological Reports</source><volume>67</volume><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.pharep.2014.10.004</pub-id><pub-id pub-id-type="pmid">25712655</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname> <given-names>PM</given-names></name><name><surname>Subramanian</surname> <given-names>SV</given-names></name><name><surname>Schooling</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Effect measure modification conceptualized using selection diagrams as mediation by mechanisms of varying population-level relevance</article-title><source>Journal of Clinical Epidemiology</source><volume>113</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2019.05.005</pub-id><pub-id pub-id-type="pmid">31121303</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>S</given-names></name><name><surname>Au Yeung</surname> <given-names>SL</given-names></name><name><surname>Zhao</surname> <given-names>JV</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Schooling</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK biobank</article-title><source>BMJ</source><volume>364</volume><elocation-id>l476</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.l476</pub-id><pub-id pub-id-type="pmid">30842065</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname> <given-names>JS</given-names></name><name><surname>Gerson</surname> <given-names>RJ</given-names></name><name><surname>Kornbrust</surname> <given-names>DJ</given-names></name><name><surname>Kloss</surname> <given-names>MW</given-names></name><name><surname>Prahalada</surname> <given-names>S</given-names></name><name><surname>Berry</surname> <given-names>PH</given-names></name><name><surname>Alberts</surname> <given-names>AW</given-names></name><name><surname>Bokelman</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Preclinical evaluation of lovastatin</article-title><source>The American Journal of Cardiology</source><volume>62</volume><fpage>J16</fpage><lpage>J27</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(88)90003-3</pub-id><pub-id pub-id-type="pmid">3055920</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname> <given-names>S</given-names></name><name><surname>Kimura</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of gonadotropin secretion by monitoring energy availability</article-title><source>Reproductive Medicine and Biology</source><volume>14</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s12522-014-0194-0</pub-id><pub-id pub-id-type="pmid">29259401</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michos</surname> <given-names>ED</given-names></name><name><surname>McEvoy</surname> <given-names>JW</given-names></name><name><surname>Blumenthal</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lipid management for the prevention of atherosclerotic cardiovascular disease</article-title><source>New England Journal of Medicine</source><volume>381</volume><fpage>1557</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1806939</pub-id><pub-id pub-id-type="pmid">31618541</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Mohammadi-Shemirani</surname> <given-names>PC</given-names></name><name><surname>Pigeyre</surname> <given-names>M</given-names></name><name><surname>Morton</surname> <given-names>M</given-names></name><name><surname>Gerstein</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Clinical benefits and adverse effects of genetically-elevated free testosterone levels: a mendelian randomization analysis</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/19005132</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname> <given-names>BA</given-names></name><name><surname>Guay</surname> <given-names>AT</given-names></name><name><surname>O'Donnell</surname> <given-names>AB</given-names></name><name><surname>McKinlay</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Normal, bound and nonbound testosterone levels in normally ageing men: results from the massachusetts male ageing study</article-title><source>Clinical Endocrinology</source><volume>62</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.2004.02174.x</pub-id><pub-id pub-id-type="pmid">15638872</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>PL</given-names></name><name><surname>Je</surname> <given-names>Y</given-names></name><name><surname>Schutz</surname> <given-names>FA</given-names></name><name><surname>Hoffman</surname> <given-names>KE</given-names></name><name><surname>Hu</surname> <given-names>JC</given-names></name><name><surname>Parekh</surname> <given-names>A</given-names></name><name><surname>Beckman</surname> <given-names>JA</given-names></name><name><surname>Choueiri</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Association of androgen deprivation therapy with cardiovascular death in patients with prostate Cancer: a meta-analysis of randomized trials</article-title><source>Jama</source><volume>306</volume><fpage>2359</fpage><lpage>2366</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.1745</pub-id><pub-id pub-id-type="pmid">22147380</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikpay</surname> <given-names>M</given-names></name><name><surname>Goel</surname> <given-names>A</given-names></name><name><surname>Won</surname> <given-names>HH</given-names></name><name><surname>Hall</surname> <given-names>LM</given-names></name><name><surname>Willenborg</surname> <given-names>C</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Saleheen</surname> <given-names>D</given-names></name><name><surname>Kyriakou</surname> <given-names>T</given-names></name><name><surname>Nelson</surname> <given-names>CP</given-names></name><name><surname>Hopewell</surname> <given-names>JC</given-names></name><name><surname>Webb</surname> <given-names>TR</given-names></name><name><surname>Zeng</surname> <given-names>L</given-names></name><name><surname>Dehghan</surname> <given-names>A</given-names></name><name><surname>Alver</surname> <given-names>M</given-names></name><name><surname>Armasu</surname> <given-names>SM</given-names></name><name><surname>Auro</surname> <given-names>K</given-names></name><name><surname>Bjonnes</surname> <given-names>A</given-names></name><name><surname>Chasman</surname> <given-names>DI</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Franceschini</surname> <given-names>N</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Grace</surname> <given-names>C</given-names></name><name><surname>Gustafsson</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Hwang</surname> <given-names>SJ</given-names></name><name><surname>Kim</surname> <given-names>YK</given-names></name><name><surname>Kleber</surname> <given-names>ME</given-names></name><name><surname>Lau</surname> <given-names>KW</given-names></name><name><surname>Lu</surname> <given-names>X</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Lyytikäinen</surname> <given-names>LP</given-names></name><name><surname>Mihailov</surname> <given-names>E</given-names></name><name><surname>Morrison</surname> <given-names>AC</given-names></name><name><surname>Pervjakova</surname> <given-names>N</given-names></name><name><surname>Qu</surname> <given-names>L</given-names></name><name><surname>Rose</surname> <given-names>LM</given-names></name><name><surname>Salfati</surname> <given-names>E</given-names></name><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Scholz</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>AV</given-names></name><name><surname>Tikkanen</surname> <given-names>E</given-names></name><name><surname>Uitterlinden</surname> <given-names>A</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Zhao</surname> <given-names>W</given-names></name><name><surname>de Andrade</surname> <given-names>M</given-names></name><name><surname>de Vries</surname> <given-names>PS</given-names></name><name><surname>van Zuydam</surname> <given-names>NR</given-names></name><name><surname>Anand</surname> <given-names>SS</given-names></name><name><surname>Bertram</surname> <given-names>L</given-names></name><name><surname>Beutner</surname> <given-names>F</given-names></name><name><surname>Dedoussis</surname> <given-names>G</given-names></name><name><surname>Frossard</surname> <given-names>P</given-names></name><name><surname>Gauguier</surname> <given-names>D</given-names></name><name><surname>Goodall</surname> <given-names>AH</given-names></name><name><surname>Gottesman</surname> <given-names>O</given-names></name><name><surname>Haber</surname> <given-names>M</given-names></name><name><surname>Han</surname> <given-names>BG</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Jalilzadeh</surname> <given-names>S</given-names></name><name><surname>Kessler</surname> <given-names>T</given-names></name><name><surname>König</surname> <given-names>IR</given-names></name><name><surname>Lannfelt</surname> <given-names>L</given-names></name><name><surname>Lieb</surname> <given-names>W</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Lokki</surname> <given-names>ML</given-names></name><name><surname>Magnusson</surname> <given-names>PK</given-names></name><name><surname>Mallick</surname> <given-names>NH</given-names></name><name><surname>Mehra</surname> <given-names>N</given-names></name><name><surname>Meitinger</surname> <given-names>T</given-names></name><name><surname>Memon</surname> <given-names>FU</given-names></name><name><surname>Morris</surname> <given-names>AP</given-names></name><name><surname>Nieminen</surname> <given-names>MS</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Peters</surname> <given-names>A</given-names></name><name><surname>Rallidis</surname> <given-names>LS</given-names></name><name><surname>Rasheed</surname> <given-names>A</given-names></name><name><surname>Samuel</surname> <given-names>M</given-names></name><name><surname>Shah</surname> <given-names>SH</given-names></name><name><surname>Sinisalo</surname> <given-names>J</given-names></name><name><surname>Stirrups</surname> <given-names>KE</given-names></name><name><surname>Trompet</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Zaman</surname> <given-names>KS</given-names></name><name><surname>Ardissino</surname> <given-names>D</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Borecki</surname> <given-names>IB</given-names></name><name><surname>Bottinger</surname> <given-names>EP</given-names></name><name><surname>Buring</surname> <given-names>JE</given-names></name><name><surname>Chambers</surname> <given-names>JC</given-names></name><name><surname>Collins</surname> <given-names>R</given-names></name><name><surname>Cupples</surname> <given-names>LA</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Demuth</surname> <given-names>I</given-names></name><name><surname>Elosua</surname> <given-names>R</given-names></name><name><surname>Epstein</surname> <given-names>SE</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Feitosa</surname> <given-names>MF</given-names></name><name><surname>Franco</surname> <given-names>OH</given-names></name><name><surname>Franzosi</surname> <given-names>MG</given-names></name><name><surname>Granger</surname> <given-names>CB</given-names></name><name><surname>Gu</surname> <given-names>D</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Hall</surname> <given-names>AS</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Harris</surname> <given-names>TB</given-names></name><name><surname>Hazen</surname> <given-names>SL</given-names></name><name><surname>Hengstenberg</surname> <given-names>C</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Iribarren</surname> <given-names>C</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Karhunen</surname> <given-names>PJ</given-names></name><name><surname>Kim</surname> <given-names>BJ</given-names></name><name><surname>Kooner</surname> <given-names>JS</given-names></name><name><surname>Kullo</surname> <given-names>IJ</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Loos</surname> <given-names>RJF</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>März</surname> <given-names>W</given-names></name><name><surname>Palmer</surname> <given-names>CN</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Quertermous</surname> <given-names>T</given-names></name><name><surname>Rader</surname> <given-names>DJ</given-names></name><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Roberts</surname> <given-names>R</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Sanghera</surname> <given-names>DK</given-names></name><name><surname>Schwartz</surname> <given-names>SM</given-names></name><name><surname>Seedorf</surname> <given-names>U</given-names></name><name><surname>Stewart</surname> <given-names>AF</given-names></name><name><surname>Stott</surname> <given-names>DJ</given-names></name><name><surname>Thiery</surname> <given-names>J</given-names></name><name><surname>Zalloua</surname> <given-names>PA</given-names></name><name><surname>O'Donnell</surname> <given-names>CJ</given-names></name><name><surname>Reilly</surname> <given-names>MP</given-names></name><name><surname>Assimes</surname> <given-names>TL</given-names></name><name><surname>Thompson</surname> <given-names>JR</given-names></name><name><surname>Erdmann</surname> <given-names>J</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Watkins</surname> <given-names>H</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>McPherson</surname> <given-names>R</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Schunkert</surname> <given-names>H</given-names></name><name><surname>Samani</surname> <given-names>NJ</given-names></name><name><surname>Farrall</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1121</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1038/ng.3396</pub-id><pub-id pub-id-type="pmid">26343387</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onasanya</surname> <given-names>O</given-names></name><name><surname>Iyer</surname> <given-names>G</given-names></name><name><surname>Lucas</surname> <given-names>E</given-names></name><name><surname>Lin</surname> <given-names>D</given-names></name><name><surname>Singh</surname> <given-names>S</given-names></name><name><surname>Alexander</surname> <given-names>GC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews</article-title><source>The Lancet Diabetes &amp; Endocrinology</source><volume>4</volume><fpage>943</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(16)30215-7</pub-id><pub-id pub-id-type="pmid">27669646</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname> <given-names>TC</given-names></name><name><surname>Raymond</surname> <given-names>A</given-names></name><name><surname>Cousins</surname> <given-names>M</given-names></name><name><surname>Favreau</surname> <given-names>C</given-names></name><name><surname>Taljaard</surname> <given-names>M</given-names></name><name><surname>Gavin</surname> <given-names>C</given-names></name><name><surname>Jolly</surname> <given-names>EE</given-names></name><name><surname>Malone</surname> <given-names>S</given-names></name><name><surname>Eapen</surname> <given-names>L</given-names></name><name><surname>Chretien</surname> <given-names>M</given-names></name><name><surname>Mbikay</surname> <given-names>M</given-names></name><name><surname>Mayne</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Relationship between testosterone, estradiol and circulating PCSK9: cross-sectional and interventional studies in humans</article-title><source>Clinica Chimica Acta</source><volume>446</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2015.03.036</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orsi</surname> <given-names>FA</given-names></name><name><surname>Biedermann</surname> <given-names>JS</given-names></name><name><surname>Kruip</surname> <given-names>M</given-names></name><name><surname>van der Meer</surname> <given-names>FJ</given-names></name><name><surname>Rosendaal</surname> <given-names>FR</given-names></name><name><surname>van Hylckama Vlieg</surname> <given-names>A</given-names></name><name><surname>Bos</surname> <given-names>MHA</given-names></name><name><surname>Leebeek</surname> <given-names>FWG</given-names></name><name><surname>Cannegieter</surname> <given-names>SC</given-names></name><name><surname>Lijfering</surname> <given-names>WM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>17</volume><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1111/jth.14364</pub-id><pub-id pub-id-type="pmid">30565854</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pignatelli</surname> <given-names>P</given-names></name><name><surname>Carnevale</surname> <given-names>R</given-names></name><name><surname>Pastori</surname> <given-names>D</given-names></name><name><surname>Cangemi</surname> <given-names>R</given-names></name><name><surname>Napoleone</surname> <given-names>L</given-names></name><name><surname>Bartimoccia</surname> <given-names>S</given-names></name><name><surname>Nocella</surname> <given-names>C</given-names></name><name><surname>Basili</surname> <given-names>S</given-names></name><name><surname>Violi</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2</article-title><source>Circulation</source><volume>126</volume><fpage>92</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.095554</pub-id><pub-id pub-id-type="pmid">22615342</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plakogiannis</surname> <given-names>R</given-names></name><name><surname>Arif</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Women versus men: is there equal benefit and safety from statins?</article-title><source>Current Atherosclerosis Reports</source><volume>18</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.1007/s11883-016-0562-9</pub-id><pub-id pub-id-type="pmid">26782824</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polderman</surname> <given-names>KH</given-names></name><name><surname>Stehouwer</surname> <given-names>CD</given-names></name><name><surname>van Kamp</surname> <given-names>GJ</given-names></name><name><surname>Dekker</surname> <given-names>GA</given-names></name><name><surname>Verheugt</surname> <given-names>FW</given-names></name><name><surname>Gooren</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Influence of sex hormones on plasma endothelin levels</article-title><source>Annals of Internal Medicine</source><volume>118</volume><fpage>429</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-118-6-199303150-00006</pub-id><pub-id pub-id-type="pmid">8439117</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rafiq</surname> <given-names>S</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Murray</surname> <given-names>A</given-names></name><name><surname>Hurst</surname> <given-names>A</given-names></name><name><surname>Stevens</surname> <given-names>K</given-names></name><name><surname>Weedon</surname> <given-names>MN</given-names></name><name><surname>Henley</surname> <given-names>W</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Bandinelli</surname> <given-names>S</given-names></name><name><surname>Corsi</surname> <given-names>AM</given-names></name><name><surname>Guralnik</surname> <given-names>JM</given-names></name><name><surname>Melzer</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects</article-title><source>Genes &amp; Immunity</source><volume>8</volume><fpage>552</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1038/sj.gene.6364414</pub-id><pub-id pub-id-type="pmid">17671508</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname> <given-names>KK</given-names></name><name><surname>Corral</surname> <given-names>P</given-names></name><name><surname>Morales</surname> <given-names>E</given-names></name><name><surname>Nicholls</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options</article-title><source>The Lancet</source><volume>394</volume><fpage>697</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31950-6</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname> <given-names>JMB</given-names></name><name><surname>Wood</surname> <given-names>AM</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Extending the MR-Egger method for multivariable mendelian randomization to correct for both measured and unmeasured pleiotropy</article-title><source>Statistics in Medicine</source><volume>36</volume><fpage>4705</fpage><lpage>4718</lpage><pub-id pub-id-type="doi">10.1002/sim.7492</pub-id><pub-id pub-id-type="pmid">28960498</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname> <given-names>TG</given-names></name><name><surname>Sanderson</surname> <given-names>E</given-names></name><name><surname>Palmer</surname> <given-names>TM</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name><name><surname>Ference</surname> <given-names>BA</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Holmes</surname> <given-names>MV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable mendelian randomisation analysis</article-title><source>PLOS Medicine</source><volume>17</volume><elocation-id>e1003062</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1003062</pub-id><pub-id pub-id-type="pmid">32203549</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Everett</surname> <given-names>BM</given-names></name><name><surname>Thuren</surname> <given-names>T</given-names></name><name><surname>MacFadyen</surname> <given-names>JG</given-names></name><name><surname>Chang</surname> <given-names>WH</given-names></name><name><surname>Ballantyne</surname> <given-names>C</given-names></name><name><surname>Fonseca</surname> <given-names>F</given-names></name><name><surname>Nicolau</surname> <given-names>J</given-names></name><name><surname>Koenig</surname> <given-names>W</given-names></name><name><surname>Anker</surname> <given-names>SD</given-names></name><name><surname>Kastelein</surname> <given-names>JJP</given-names></name><name><surname>Cornel</surname> <given-names>JH</given-names></name><name><surname>Pais</surname> <given-names>P</given-names></name><name><surname>Pella</surname> <given-names>D</given-names></name><name><surname>Genest</surname> <given-names>J</given-names></name><name><surname>Cifkova</surname> <given-names>R</given-names></name><name><surname>Lorenzatti</surname> <given-names>A</given-names></name><name><surname>Forster</surname> <given-names>T</given-names></name><name><surname>Kobalava</surname> <given-names>Z</given-names></name><name><surname>Vida-Simiti</surname> <given-names>L</given-names></name><name><surname>Flather</surname> <given-names>M</given-names></name><name><surname>Shimokawa</surname> <given-names>H</given-names></name><name><surname>Ogawa</surname> <given-names>H</given-names></name><name><surname>Dellborg</surname> <given-names>M</given-names></name><name><surname>Rossi</surname> <given-names>PRF</given-names></name><name><surname>Troquay</surname> <given-names>RPT</given-names></name><name><surname>Libby</surname> <given-names>P</given-names></name><name><surname>Glynn</surname> <given-names>RJ</given-names></name><collab>CANTOS Trial Group</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title><source>New England Journal of Medicine</source><volume>377</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id><pub-id pub-id-type="pmid">28845751</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosselli</surname> <given-names>M</given-names></name><name><surname>Keller</surname> <given-names>PJ</given-names></name><name><surname>Dubey</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Role of nitric oxide in the biology, physiology and pathophysiology of reproduction</article-title><source>Human Reproduction Update</source><volume>4</volume><fpage>3</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1093/humupd/4.1.3</pub-id><pub-id pub-id-type="pmid">9622410</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruth</surname> <given-names>KS</given-names></name><name><surname>Day</surname> <given-names>FR</given-names></name><name><surname>Tyrrell</surname> <given-names>J</given-names></name><name><surname>Thompson</surname> <given-names>DJ</given-names></name><name><surname>Wood</surname> <given-names>AR</given-names></name><name><surname>Mahajan</surname> <given-names>A</given-names></name><name><surname>Beaumont</surname> <given-names>RN</given-names></name><name><surname>Wittemans</surname> <given-names>L</given-names></name><name><surname>Martin</surname> <given-names>S</given-names></name><name><surname>Busch</surname> <given-names>AS</given-names></name><name><surname>Erzurumluoglu</surname> <given-names>AM</given-names></name><name><surname>Hollis</surname> <given-names>B</given-names></name><name><surname>O'Mara</surname> <given-names>TA</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Easton</surname> <given-names>DF</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name><name><surname>Murray</surname> <given-names>A</given-names></name><name><surname>Ong</surname> <given-names>KK</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Perry</surname> <given-names>JRB</given-names></name><collab>Endometrial Cancer Association Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Using human genetics to understand the disease impacts of testosterone in men and women</article-title><source>Nature Medicine</source><volume>26</volume><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0751-5</pub-id><pub-id pub-id-type="pmid">32042192</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahebkar</surname> <given-names>A</given-names></name><name><surname>Kotani</surname> <given-names>K</given-names></name><name><surname>Serban</surname> <given-names>C</given-names></name><name><surname>Ursoniu</surname> <given-names>S</given-names></name><name><surname>Mikhailidis</surname> <given-names>DP</given-names></name><name><surname>Jones</surname> <given-names>SR</given-names></name><name><surname>Ray</surname> <given-names>KK</given-names></name><name><surname>Blaha</surname> <given-names>MJ</given-names></name><name><surname>Rysz</surname> <given-names>J</given-names></name><name><surname>Toth</surname> <given-names>PP</given-names></name><name><surname>Muntner</surname> <given-names>P</given-names></name><name><surname>Lip</surname> <given-names>GY</given-names></name><name><surname>Banach</surname> <given-names>M</given-names></name><collab>Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials</article-title><source>Atherosclerosis</source><volume>241</volume><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.05.022</pub-id><pub-id pub-id-type="pmid">26074317</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahebkar</surname> <given-names>A</given-names></name><name><surname>Serban</surname> <given-names>C</given-names></name><name><surname>Ursoniu</surname> <given-names>S</given-names></name><name><surname>Mikhailidis</surname> <given-names>DP</given-names></name><name><surname>Undas</surname> <given-names>A</given-names></name><name><surname>Lip</surname> <given-names>GY</given-names></name><name><surname>Bittner</surname> <given-names>V</given-names></name><name><surname>Ray</surname> <given-names>K</given-names></name><name><surname>Watts</surname> <given-names>GF</given-names></name><name><surname>Hovingh</surname> <given-names>GK</given-names></name><name><surname>Rysz</surname> <given-names>J</given-names></name><name><surname>Kastelein</surname> <given-names>JJ</given-names></name><name><surname>Banach</surname> <given-names>M</given-names></name><collab>Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</collab></person-group><year iso-8601-date="2016">2016</year><article-title>The impact of statin therapy on plasma levels of von willebrand factor antigen. systematic review and meta-analysis of randomised placebo-controlled trials</article-title><source>Thrombosis and Haemostasis</source><volume>115</volume><fpage>520</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1160/TH15-08-0620</pub-id><pub-id pub-id-type="pmid">26632869</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanderson</surname> <given-names>E</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Windmeijer</surname> <given-names>F</given-names></name><name><surname>Bowden</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An examination of multivariable mendelian randomization in the single-sample and two-sample summary data settings</article-title><source>International Journal of Epidemiology</source><volume>48</volume><fpage>713</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy262</pub-id><pub-id pub-id-type="pmid">30535378</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanderson</surname> <given-names>E</given-names></name><name><surname>Windmeijer</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A weak instrument [Formula: see text]-test in linear IV models with multiple endogenous variables</article-title><source>Journal of Econometrics</source><volume>190</volume><fpage>212</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.jeconom.2015.06.004</pub-id><pub-id pub-id-type="pmid">29129953</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname> <given-names>AF</given-names></name><name><surname>Pearce</surname> <given-names>LS</given-names></name><name><surname>Wilkins</surname> <given-names>JT</given-names></name><name><surname>Overington</surname> <given-names>JP</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Casas</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease</article-title><source>Cochrane Database of Systematic Reviews</source><volume>4</volume><elocation-id>Cd011748</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD011748.pub2</pub-id><pub-id pub-id-type="pmid">28453187</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schonbeck</surname> <given-names>U</given-names></name><name><surname>Libby</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?</article-title><source>Circulation</source><volume>109</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000129505.34151.23</pub-id><pub-id pub-id-type="pmid">15173059</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name><name><surname>Au Yeung</surname> <given-names>SL</given-names></name><name><surname>Freeman</surname> <given-names>G</given-names></name><name><surname>Cowling</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials</article-title><source>BMC Medicine</source><volume>11</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7015-11-57</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name><name><surname>Au Yeung</surname> <given-names>SL</given-names></name><name><surname>Leung</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Why do statins reduce cardiovascular disease more than other lipid modulating therapies?</article-title><source>European Journal of Clinical Investigation</source><volume>44</volume><fpage>1135</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1111/eci.12342</pub-id><pub-id pub-id-type="pmid">25252212</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Could androgens be relevant to partly explain why men have lower life expectancy than women?</article-title><source>Journal of Epidemiology and Community Health</source><volume>70</volume><fpage>324</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1136/jech-2015-206336</pub-id><pub-id pub-id-type="pmid">26659456</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?</article-title><source>The Lancet</source><volume>390</volume><fpage>709</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31648-8</pub-id><pub-id pub-id-type="pmid">28359648</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name><name><surname>Luo</surname> <given-names>S</given-names></name><name><surname>Au Yeung</surname> <given-names>SL</given-names></name><name><surname>Thompson</surname> <given-names>DJ</given-names></name><name><surname>Karthikeyan</surname> <given-names>S</given-names></name><name><surname>Bolton</surname> <given-names>TR</given-names></name><name><surname>Mason</surname> <given-names>AM</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Burgess</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Genetic predictors of testosterone and their associations with cardiovascular disease and risk factors: a mendelian randomization investigation</article-title><source>International Journal of Cardiology</source><volume>267</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2018.05.051</pub-id><pub-id pub-id-type="pmid">29804699</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name><name><surname>Kodali</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Borrell</surname> <given-names>LN</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>ET (Endothelin)-1 and ischemic heart disease: a mendelian randomization study</article-title><source>Circulation. Genomic and Precision Medicine</source><volume>11</volume><elocation-id>e002026</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.117.002026</pub-id><pub-id pub-id-type="pmid">29555672</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name><name><surname>Lopez</surname> <given-names>PM</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Zhao</surname> <given-names>JV</given-names></name><name><surname>Au Yeung</surname> <given-names>SL</given-names></name><name><surname>Huang</surname> <given-names>JV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Use of multivariable mendelian randomization to address biases due to competing risk before recruitment</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/716621</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name><name><surname>Ng</surname> <given-names>JCM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reproduction and longevity: a mendelian randomization study of gonadotropin-releasing hormone and ischemic heart disease</article-title><source>SSM - Population Health</source><volume>8</volume><elocation-id>100411</elocation-id><pub-id pub-id-type="doi">10.1016/j.ssmph.2019.100411</pub-id><pub-id pub-id-type="pmid">31198836</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schooling</surname> <given-names>CM</given-names></name><name><surname>Zhao</surname> <given-names>JV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>How might bromodomain and Extra-Terminal (BET) Inhibitors operate in cardiovascular disease?</article-title><source>American Journal of Cardiovascular Drugs</source><volume>19</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1007/s40256-018-00315-3</pub-id><pub-id pub-id-type="pmid">30693439</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serban</surname> <given-names>C</given-names></name><name><surname>Sahebkar</surname> <given-names>A</given-names></name><name><surname>Ursoniu</surname> <given-names>S</given-names></name><name><surname>Mikhailidis</surname> <given-names>DP</given-names></name><name><surname>Rizzo</surname> <given-names>M</given-names></name><name><surname>Lip</surname> <given-names>GY</given-names></name><name><surname>Kees Hovingh</surname> <given-names>G</given-names></name><name><surname>Kastelein</surname> <given-names>JJ</given-names></name><name><surname>Kalinowski</surname> <given-names>L</given-names></name><name><surname>Rysz</surname> <given-names>J</given-names></name><name><surname>Banach</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>9902</elocation-id><pub-id pub-id-type="doi">10.1038/srep09902</pub-id><pub-id pub-id-type="pmid">25970700</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu-Albergine</surname> <given-names>M</given-names></name><name><surname>Van Yserloo</surname> <given-names>B</given-names></name><name><surname>Golkowski</surname> <given-names>MG</given-names></name><name><surname>Ong</surname> <given-names>SE</given-names></name><name><surname>Beavo</surname> <given-names>JA</given-names></name><name><surname>Bornfeldt</surname> <given-names>KE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SCAP/SREBP pathway is required for the full steroidogenic response to cyclic AMP</article-title><source>PNAS</source><volume>113</volume><fpage>E5685</fpage><lpage>E5693</lpage><pub-id pub-id-type="doi">10.1073/pnas.1611424113</pub-id><pub-id pub-id-type="pmid">27601673</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Sinnott-Armstrong</surname> <given-names>N</given-names></name><name><surname>Tanigawa</surname> <given-names>Y</given-names></name><name><surname>Amar</surname> <given-names>D</given-names></name><name><surname>Mars</surname> <given-names>NJ</given-names></name><name><surname>Aguirre</surname> <given-names>M</given-names></name><name><surname>Venkataraman</surname> <given-names>GR</given-names></name><name><surname>Wainberg</surname> <given-names>M</given-names></name><name><surname>Ollila</surname> <given-names>HN</given-names></name><name><surname>Pirruccello</surname> <given-names>JP</given-names></name><name><surname>Qian</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetics of 38 blood and urine biomarkers in the UK biobank</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/660506</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sliz</surname> <given-names>E</given-names></name><name><surname>Kettunen</surname> <given-names>J</given-names></name><name><surname>Holmes</surname> <given-names>MV</given-names></name><name><surname>Williams</surname> <given-names>CO</given-names></name><name><surname>Boachie</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Männikkö</surname> <given-names>M</given-names></name><name><surname>Sebert</surname> <given-names>S</given-names></name><name><surname>Walters</surname> <given-names>R</given-names></name><name><surname>Lin</surname> <given-names>K</given-names></name><name><surname>Millwood</surname> <given-names>IY</given-names></name><name><surname>Clarke</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Rankin</surname> <given-names>N</given-names></name><name><surname>Welsh</surname> <given-names>P</given-names></name><name><surname>Delles</surname> <given-names>C</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Trompet</surname> <given-names>S</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Järvelin</surname> <given-names>MR</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name><name><surname>Butterworth</surname> <given-names>A</given-names></name><name><surname>Würtz</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment</article-title><source>Circulation</source><volume>138</volume><fpage>2499</fpage><lpage>2512</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034942</pub-id><pub-id pub-id-type="pmid">30524137</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Ebrahim</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?</article-title><source>International Journal of Epidemiology</source><volume>32</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/ije/dyg070</pub-id><pub-id pub-id-type="pmid">12689998</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swerdlow</surname> <given-names>DI</given-names></name><name><surname>Holmes</surname> <given-names>MV</given-names></name><name><surname>Kuchenbaecker</surname> <given-names>KB</given-names></name><name><surname>Engmann</surname> <given-names>JE</given-names></name><name><surname>Shah</surname> <given-names>T</given-names></name><name><surname>Sofat</surname> <given-names>R</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Chung</surname> <given-names>C</given-names></name><name><surname>Peasey</surname> <given-names>A</given-names></name><name><surname>Pfister</surname> <given-names>R</given-names></name><name><surname>Mooijaart</surname> <given-names>SP</given-names></name><name><surname>Ireland</surname> <given-names>HA</given-names></name><name><surname>Leusink</surname> <given-names>M</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>KW</given-names></name><name><surname>Palmen</surname> <given-names>J</given-names></name><name><surname>Howard</surname> <given-names>P</given-names></name><name><surname>Cooper</surname> <given-names>JA</given-names></name><name><surname>Drenos</surname> <given-names>F</given-names></name><name><surname>Hardy</surname> <given-names>J</given-names></name><name><surname>Nalls</surname> <given-names>MA</given-names></name><name><surname>Li</surname> <given-names>YR</given-names></name><name><surname>Lowe</surname> <given-names>G</given-names></name><name><surname>Stewart</surname> <given-names>M</given-names></name><name><surname>Bielinski</surname> <given-names>SJ</given-names></name><name><surname>Peto</surname> <given-names>J</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Gallacher</surname> <given-names>J</given-names></name><name><surname>Dunlop</surname> <given-names>M</given-names></name><name><surname>Houlston</surname> <given-names>R</given-names></name><name><surname>Tomlinson</surname> <given-names>I</given-names></name><name><surname>Tzoulaki</surname> <given-names>I</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Boer</surname> <given-names>JM</given-names></name><name><surname>Forouhi</surname> <given-names>NG</given-names></name><name><surname>Onland-Moret</surname> <given-names>NC</given-names></name><name><surname>van der Schouw</surname> <given-names>YT</given-names></name><name><surname>Schnabel</surname> <given-names>RB</given-names></name><name><surname>Hubacek</surname> <given-names>JA</given-names></name><name><surname>Kubinova</surname> <given-names>R</given-names></name><name><surname>Baceviciene</surname> <given-names>M</given-names></name><name><surname>Tamosiunas</surname> <given-names>A</given-names></name><name><surname>Pajak</surname> <given-names>A</given-names></name><name><surname>Topor-Madry</surname> <given-names>R</given-names></name><name><surname>Malyutina</surname> <given-names>S</given-names></name><name><surname>Baldassarre</surname> <given-names>D</given-names></name><name><surname>Sennblad</surname> <given-names>B</given-names></name><name><surname>Tremoli</surname> <given-names>E</given-names></name><name><surname>de Faire</surname> <given-names>U</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Bandenelli</surname> <given-names>S</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Meschia</surname> <given-names>JF</given-names></name><name><surname>Singleton</surname> <given-names>A</given-names></name><name><surname>Navis</surname> <given-names>G</given-names></name><name><surname>Mateo Leach</surname> <given-names>I</given-names></name><name><surname>Bakker</surname> <given-names>SJ</given-names></name><name><surname>Gansevoort</surname> <given-names>RT</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Epstein</surname> <given-names>SE</given-names></name><name><surname>Burnett</surname> <given-names>MS</given-names></name><name><surname>Devaney</surname> <given-names>JM</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Westendorp</surname> <given-names>RG</given-names></name><name><surname>Jan de Borst</surname> <given-names>G</given-names></name><name><surname>van der Graaf</surname> <given-names>Y</given-names></name><name><surname>de Jong</surname> <given-names>PA</given-names></name><name><surname>Mailand-van der Zee</surname> <given-names>AH</given-names></name><name><surname>Klungel</surname> <given-names>OH</given-names></name><name><surname>de Boer</surname> <given-names>A</given-names></name><name><surname>Doevendans</surname> <given-names>PA</given-names></name><name><surname>Stephens</surname> <given-names>JW</given-names></name><name><surname>Eaton</surname> <given-names>CB</given-names></name><name><surname>Robinson</surname> <given-names>JG</given-names></name><name><surname>Manson</surname> <given-names>JE</given-names></name><name><surname>Fowkes</surname> <given-names>FG</given-names></name><name><surname>Frayling</surname> <given-names>TM</given-names></name><name><surname>Price</surname> <given-names>JF</given-names></name><name><surname>Whincup</surname> <given-names>PH</given-names></name><name><surname>Morris</surname> <given-names>RW</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Ben-Shlomo</surname> <given-names>Y</given-names></name><name><surname>Redline</surname> <given-names>S</given-names></name><name><surname>Lange</surname> <given-names>LA</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Verschuren</surname> <given-names>WM</given-names></name><name><surname>Benjamin</surname> <given-names>EJ</given-names></name><name><surname>Whittaker</surname> <given-names>JC</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Dudbridge</surname> <given-names>F</given-names></name><name><surname>Delaney</surname> <given-names>JA</given-names></name><name><surname>Wong</surname> <given-names>A</given-names></name><name><surname>Kuh</surname> <given-names>D</given-names></name><name><surname>Hardy</surname> <given-names>R</given-names></name><name><surname>Castillo</surname> <given-names>BA</given-names></name><name><surname>Connolly</surname> <given-names>JJ</given-names></name><name><surname>van der Harst</surname> <given-names>P</given-names></name><name><surname>Brunner</surname> <given-names>EJ</given-names></name><name><surname>Marmot</surname> <given-names>MG</given-names></name><name><surname>Wassel</surname> <given-names>CL</given-names></name><name><surname>Humphries</surname> <given-names>SE</given-names></name><name><surname>Talmud</surname> <given-names>PJ</given-names></name><name><surname>Kivimaki</surname> <given-names>M</given-names></name><name><surname>Asselbergs</surname> <given-names>FW</given-names></name><name><surname>Voevoda</surname> <given-names>M</given-names></name><name><surname>Bobak</surname> <given-names>M</given-names></name><name><surname>Pikhart</surname> <given-names>H</given-names></name><name><surname>Wilson</surname> <given-names>JG</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Reiner</surname> <given-names>AP</given-names></name><name><surname>Keating</surname> <given-names>BJ</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Casas</surname> <given-names>JP</given-names></name><collab>Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis</article-title><source>Lancet</source><volume>379</volume><fpage>1214</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60110-X</pub-id><pub-id pub-id-type="pmid">22421340</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swerdlow</surname> <given-names>DI</given-names></name><name><surname>Preiss</surname> <given-names>D</given-names></name><name><surname>Kuchenbaecker</surname> <given-names>KB</given-names></name><name><surname>Holmes</surname> <given-names>MV</given-names></name><name><surname>Engmann</surname> <given-names>JEL</given-names></name><name><surname>Shah</surname> <given-names>T</given-names></name><name><surname>Sofat</surname> <given-names>R</given-names></name><name><surname>Stender</surname> <given-names>S</given-names></name><name><surname>Johnson</surname> <given-names>PCD</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Leusink</surname> <given-names>M</given-names></name><name><surname>Verweij</surname> <given-names>N</given-names></name><name><surname>Sharp</surname> <given-names>SJ</given-names></name><name><surname>Guo</surname> <given-names>Y</given-names></name><name><surname>Giambartolomei</surname> <given-names>C</given-names></name><name><surname>Chung</surname> <given-names>C</given-names></name><name><surname>Peasey</surname> <given-names>A</given-names></name><name><surname>Amuzu</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Palmen</surname> <given-names>J</given-names></name><name><surname>Howard</surname> <given-names>P</given-names></name><name><surname>Cooper</surname> <given-names>JA</given-names></name><name><surname>Drenos</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>YR</given-names></name><name><surname>Lowe</surname> <given-names>G</given-names></name><name><surname>Gallacher</surname> <given-names>J</given-names></name><name><surname>Stewart</surname> <given-names>MCW</given-names></name><name><surname>Tzoulaki</surname> <given-names>I</given-names></name><name><surname>Buxbaum</surname> <given-names>SG</given-names></name><name><surname>van der A</surname> <given-names>DL</given-names></name><name><surname>Forouhi</surname> <given-names>NG</given-names></name><name><surname>Onland-Moret</surname> <given-names>NC</given-names></name><name><surname>van der Schouw</surname> <given-names>YT</given-names></name><name><surname>Schnabel</surname> <given-names>RB</given-names></name><name><surname>Hubacek</surname> <given-names>JA</given-names></name><name><surname>Kubinova</surname> <given-names>R</given-names></name><name><surname>Baceviciene</surname> <given-names>M</given-names></name><name><surname>Tamosiunas</surname> <given-names>A</given-names></name><name><surname>Pajak</surname> <given-names>A</given-names></name><name><surname>Topor-Madry</surname> <given-names>R</given-names></name><name><surname>Stepaniak</surname> <given-names>U</given-names></name><name><surname>Malyutina</surname> <given-names>S</given-names></name><name><surname>Baldassarre</surname> <given-names>D</given-names></name><name><surname>Sennblad</surname> <given-names>B</given-names></name><name><surname>Tremoli</surname> <given-names>E</given-names></name><name><surname>de Faire</surname> <given-names>U</given-names></name><name><surname>Veglia</surname> <given-names>F</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Westendorp</surname> <given-names>RGJ</given-names></name><name><surname>de Borst</surname> <given-names>GJ</given-names></name><name><surname>de Jong</surname> <given-names>PA</given-names></name><name><surname>Algra</surname> <given-names>A</given-names></name><name><surname>Spiering</surname> <given-names>W</given-names></name><name><surname>der Zee</surname> <given-names>AHM</given-names></name><name><surname>Klungel</surname> <given-names>OH</given-names></name><name><surname>de Boer</surname> <given-names>A</given-names></name><name><surname>Doevendans</surname> <given-names>PA</given-names></name><name><surname>Eaton</surname> <given-names>CB</given-names></name><name><surname>Robinson</surname> <given-names>JG</given-names></name><name><surname>Duggan</surname> <given-names>D</given-names></name><name><surname>Kjekshus</surname> <given-names>J</given-names></name><name><surname>Downs</surname> <given-names>JR</given-names></name><name><surname>Gotto</surname> <given-names>AM</given-names></name><name><surname>Keech</surname> <given-names>AC</given-names></name><name><surname>Marchioli</surname> <given-names>R</given-names></name><name><surname>Tognoni</surname> <given-names>G</given-names></name><name><surname>Sever</surname> <given-names>PS</given-names></name><name><surname>Poulter</surname> <given-names>NR</given-names></name><name><surname>Waters</surname> <given-names>DD</given-names></name><name><surname>Pedersen</surname> <given-names>TR</given-names></name><name><surname>Amarenco</surname> <given-names>P</given-names></name><name><surname>Nakamura</surname> <given-names>H</given-names></name><name><surname>McMurray</surname> <given-names>JJV</given-names></name><name><surname>Lewsey</surname> <given-names>JD</given-names></name><name><surname>Chasman</surname> <given-names>DI</given-names></name><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Maggioni</surname> <given-names>AP</given-names></name><name><surname>Tavazzi</surname> <given-names>L</given-names></name><name><surname>Ray</surname> <given-names>KK</given-names></name><name><surname>Seshasai</surname> <given-names>SRK</given-names></name><name><surname>Manson</surname> <given-names>JE</given-names></name><name><surname>Price</surname> <given-names>JF</given-names></name><name><surname>Whincup</surname> <given-names>PH</given-names></name><name><surname>Morris</surname> <given-names>RW</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Smith</surname> <given-names>GD</given-names></name><name><surname>Ben-Shlomo</surname> <given-names>Y</given-names></name><name><surname>Schreiner</surname> <given-names>PJ</given-names></name><name><surname>Fornage</surname> <given-names>M</given-names></name><name><surname>Siscovick</surname> <given-names>DS</given-names></name><name><surname>Cushman</surname> <given-names>M</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Verschuren</surname> <given-names>WMM</given-names></name><name><surname>Redline</surname> <given-names>S</given-names></name><name><surname>Patel</surname> <given-names>SR</given-names></name><name><surname>Whittaker</surname> <given-names>JC</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Delaney</surname> <given-names>JA</given-names></name><name><surname>Dale</surname> <given-names>C</given-names></name><name><surname>Gaunt</surname> <given-names>TR</given-names></name><name><surname>Wong</surname> <given-names>A</given-names></name><name><surname>Kuh</surname> <given-names>D</given-names></name><name><surname>Hardy</surname> <given-names>R</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>Castillo</surname> <given-names>BA</given-names></name><name><surname>van der Harst</surname> <given-names>P</given-names></name><name><surname>Brunner</surname> <given-names>EJ</given-names></name><name><surname>Tybjaerg-Hansen</surname> <given-names>A</given-names></name><name><surname>Marmot</surname> <given-names>MG</given-names></name><name><surname>Krauss</surname> <given-names>RM</given-names></name><name><surname>Tsai</surname> <given-names>M</given-names></name><name><surname>Coresh</surname> <given-names>J</given-names></name><name><surname>Hoogeveen</surname> <given-names>RC</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Lange</surname> <given-names>LA</given-names></name><name><surname>Hakonarson</surname> <given-names>H</given-names></name><name><surname>Dudbridge</surname> <given-names>F</given-names></name><name><surname>Humphries</surname> <given-names>SE</given-names></name><name><surname>Talmud</surname> <given-names>PJ</given-names></name><name><surname>Kivimäki</surname> <given-names>M</given-names></name><name><surname>Timpson</surname> <given-names>NJ</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Asselbergs</surname> <given-names>FW</given-names></name><name><surname>Voevoda</surname> <given-names>M</given-names></name><name><surname>Bobak</surname> <given-names>M</given-names></name><name><surname>Pikhart</surname> <given-names>H</given-names></name><name><surname>Wilson</surname> <given-names>JG</given-names></name><name><surname>Reiner</surname> <given-names>AP</given-names></name><name><surname>Keating</surname> <given-names>BJ</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials</article-title><source>The Lancet</source><volume>385</volume><fpage>351</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61183-1</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardif</surname> <given-names>JC</given-names></name><name><surname>Kouz</surname> <given-names>S</given-names></name><name><surname>Waters</surname> <given-names>DD</given-names></name><name><surname>Bertrand</surname> <given-names>OF</given-names></name><name><surname>Diaz</surname> <given-names>R</given-names></name><name><surname>Maggioni</surname> <given-names>AP</given-names></name><name><surname>Pinto</surname> <given-names>FJ</given-names></name><name><surname>Ibrahim</surname> <given-names>R</given-names></name><name><surname>Gamra</surname> <given-names>H</given-names></name><name><surname>Kiwan</surname> <given-names>GS</given-names></name><name><surname>Berry</surname> <given-names>C</given-names></name><name><surname>López-Sendón</surname> <given-names>J</given-names></name><name><surname>Ostadal</surname> <given-names>P</given-names></name><name><surname>Koenig</surname> <given-names>W</given-names></name><name><surname>Angoulvant</surname> <given-names>D</given-names></name><name><surname>Grégoire</surname> <given-names>JC</given-names></name><name><surname>Lavoie</surname> <given-names>MA</given-names></name><name><surname>Dubé</surname> <given-names>MP</given-names></name><name><surname>Rhainds</surname> <given-names>D</given-names></name><name><surname>Provencher</surname> <given-names>M</given-names></name><name><surname>Blondeau</surname> <given-names>L</given-names></name><name><surname>Orfanos</surname> <given-names>A</given-names></name><name><surname>L'Allier</surname> <given-names>PL</given-names></name><name><surname>Guertin</surname> <given-names>MC</given-names></name><name><surname>Roubille</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Efficacy and safety of Low-Dose colchicine after myocardial infarction</article-title><source>New England Journal of Medicine</source><volume>381</volume><fpage>2497</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1912388</pub-id><pub-id pub-id-type="pmid">31733140</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname> <given-names>DQ</given-names></name><name><surname>Ramos</surname> <given-names>EH</given-names></name><name><surname>Belsham</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Induction of gnrh mRNA expression by the ω-3 polyunsaturated fatty acid docosahexaenoic acid and the saturated fatty acid palmitate in a GnRH-synthesizing neuronal cell model, mHypoA-GnRH/GFP</article-title><source>Molecular and Cellular Endocrinology</source><volume>426</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2016.02.019</pub-id><pub-id pub-id-type="pmid">26923440</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremellen</surname> <given-names>K</given-names></name><name><surname>McPhee</surname> <given-names>N</given-names></name><name><surname>Pearce</surname> <given-names>K</given-names></name><name><surname>Benson</surname> <given-names>S</given-names></name><name><surname>Schedlowski</surname> <given-names>M</given-names></name><name><surname>Engler</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Endotoxin-initiated inflammation reduces testosterone production in men of reproductive age</article-title><source>American Journal of Physiology-Endocrinology and Metabolism</source><volume>314</volume><fpage>E206</fpage><lpage>E213</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00279.2017</pub-id><pub-id pub-id-type="pmid">29183872</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kesteren</surname> <given-names>PJ</given-names></name><name><surname>Kooistra</surname> <given-names>T</given-names></name><name><surname>Lansink</surname> <given-names>M</given-names></name><name><surname>van Kamp</surname> <given-names>GJ</given-names></name><name><surname>Asscheman</surname> <given-names>H</given-names></name><name><surname>Gooren</surname> <given-names>LJ</given-names></name><name><surname>Emeis</surname> <given-names>JJ</given-names></name><name><surname>Vischer</surname> <given-names>UM</given-names></name><name><surname>Stehouwer</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning</article-title><source>Thrombosis and Haemostasis</source><volume>79</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1055/s-0037-1615115</pub-id><pub-id pub-id-type="pmid">9609242</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willer</surname> <given-names>CJ</given-names></name><name><surname>Schmidt</surname> <given-names>EM</given-names></name><name><surname>Sengupta</surname> <given-names>S</given-names></name><name><surname>Peloso</surname> <given-names>GM</given-names></name><name><surname>Gustafsson</surname> <given-names>S</given-names></name><name><surname>Kanoni</surname> <given-names>S</given-names></name><name><surname>Ganna</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Buchkovich</surname> <given-names>ML</given-names></name><name><surname>Mora</surname> <given-names>S</given-names></name><name><surname>Beckmann</surname> <given-names>JS</given-names></name><name><surname>Bragg-Gresham</surname> <given-names>JL</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Demirkan</surname> <given-names>A</given-names></name><name><surname>Den Hertog</surname> <given-names>HM</given-names></name><name><surname>Do</surname> <given-names>R</given-names></name><name><surname>Donnelly</surname> <given-names>LA</given-names></name><name><surname>Ehret</surname> <given-names>GB</given-names></name><name><surname>Esko</surname> <given-names>T</given-names></name><name><surname>Feitosa</surname> <given-names>MF</given-names></name><name><surname>Ferreira</surname> <given-names>T</given-names></name><name><surname>Fischer</surname> <given-names>K</given-names></name><name><surname>Fontanillas</surname> <given-names>P</given-names></name><name><surname>Fraser</surname> <given-names>RM</given-names></name><name><surname>Freitag</surname> <given-names>DF</given-names></name><name><surname>Gurdasani</surname> <given-names>D</given-names></name><name><surname>Heikkilä</surname> <given-names>K</given-names></name><name><surname>Hyppönen</surname> <given-names>E</given-names></name><name><surname>Isaacs</surname> <given-names>A</given-names></name><name><surname>Jackson</surname> <given-names>AU</given-names></name><name><surname>Johansson</surname> <given-names>Å</given-names></name><name><surname>Johnson</surname> <given-names>T</given-names></name><name><surname>Kaakinen</surname> <given-names>M</given-names></name><name><surname>Kettunen</surname> <given-names>J</given-names></name><name><surname>Kleber</surname> <given-names>ME</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Luan</surname> <given-names>J</given-names></name><name><surname>Lyytikäinen</surname> <given-names>LP</given-names></name><name><surname>Magnusson</surname> <given-names>PKE</given-names></name><name><surname>Mangino</surname> <given-names>M</given-names></name><name><surname>Mihailov</surname> <given-names>E</given-names></name><name><surname>Montasser</surname> <given-names>ME</given-names></name><name><surname>Müller-Nurasyid</surname> <given-names>M</given-names></name><name><surname>Nolte</surname> <given-names>IM</given-names></name><name><surname>O'Connell</surname> <given-names>JR</given-names></name><name><surname>Palmer</surname> <given-names>CD</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Petersen</surname> <given-names>AK</given-names></name><name><surname>Sanna</surname> <given-names>S</given-names></name><name><surname>Saxena</surname> <given-names>R</given-names></name><name><surname>Service</surname> <given-names>SK</given-names></name><name><surname>Shah</surname> <given-names>S</given-names></name><name><surname>Shungin</surname> <given-names>D</given-names></name><name><surname>Sidore</surname> <given-names>C</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Strawbridge</surname> <given-names>RJ</given-names></name><name><surname>Surakka</surname> <given-names>I</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Teslovich</surname> <given-names>TM</given-names></name><name><surname>Thorleifsson</surname> <given-names>G</given-names></name><name><surname>Van den Herik</surname> <given-names>EG</given-names></name><name><surname>Voight</surname> <given-names>BF</given-names></name><name><surname>Volcik</surname> <given-names>KA</given-names></name><name><surname>Waite</surname> <given-names>LL</given-names></name><name><surname>Wong</surname> <given-names>A</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Absher</surname> <given-names>D</given-names></name><name><surname>Asiki</surname> <given-names>G</given-names></name><name><surname>Barroso</surname> <given-names>I</given-names></name><name><surname>Been</surname> <given-names>LF</given-names></name><name><surname>Bolton</surname> <given-names>JL</given-names></name><name><surname>Bonnycastle</surname> <given-names>LL</given-names></name><name><surname>Brambilla</surname> <given-names>P</given-names></name><name><surname>Burnett</surname> <given-names>MS</given-names></name><name><surname>Cesana</surname> <given-names>G</given-names></name><name><surname>Dimitriou</surname> <given-names>M</given-names></name><name><surname>Doney</surname> <given-names>ASF</given-names></name><name><surname>Döring</surname> <given-names>A</given-names></name><name><surname>Elliott</surname> <given-names>P</given-names></name><name><surname>Epstein</surname> <given-names>SE</given-names></name><name><surname>Ingi Eyjolfsson</surname> <given-names>G</given-names></name><name><surname>Gigante</surname> <given-names>B</given-names></name><name><surname>Goodarzi</surname> <given-names>MO</given-names></name><name><surname>Grallert</surname> <given-names>H</given-names></name><name><surname>Gravito</surname> <given-names>ML</given-names></name><name><surname>Groves</surname> <given-names>CJ</given-names></name><name><surname>Hallmans</surname> <given-names>G</given-names></name><name><surname>Hartikainen</surname> <given-names>AL</given-names></name><name><surname>Hayward</surname> <given-names>C</given-names></name><name><surname>Hernandez</surname> <given-names>D</given-names></name><name><surname>Hicks</surname> <given-names>AA</given-names></name><name><surname>Holm</surname> <given-names>H</given-names></name><name><surname>Hung</surname> <given-names>YJ</given-names></name><name><surname>Illig</surname> <given-names>T</given-names></name><name><surname>Jones</surname> <given-names>MR</given-names></name><name><surname>Kaleebu</surname> <given-names>P</given-names></name><name><surname>Kastelein</surname> <given-names>JJP</given-names></name><name><surname>Khaw</surname> <given-names>KT</given-names></name><name><surname>Kim</surname> <given-names>E</given-names></name><name><surname>Klopp</surname> <given-names>N</given-names></name><name><surname>Komulainen</surname> <given-names>P</given-names></name><name><surname>Kumari</surname> <given-names>M</given-names></name><name><surname>Langenberg</surname> <given-names>C</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Lin</surname> <given-names>SY</given-names></name><name><surname>Lindström</surname> <given-names>J</given-names></name><name><surname>Loos</surname> <given-names>RJF</given-names></name><name><surname>Mach</surname> <given-names>F</given-names></name><name><surname>McArdle</surname> <given-names>WL</given-names></name><name><surname>Meisinger</surname> <given-names>C</given-names></name><name><surname>Mitchell</surname> <given-names>BD</given-names></name><name><surname>Müller</surname> <given-names>G</given-names></name><name><surname>Nagaraja</surname> <given-names>R</given-names></name><name><surname>Narisu</surname> <given-names>N</given-names></name><name><surname>Nieminen</surname> <given-names>TVM</given-names></name><name><surname>Nsubuga</surname> <given-names>RN</given-names></name><name><surname>Olafsson</surname> <given-names>I</given-names></name><name><surname>Ong</surname> <given-names>KK</given-names></name><name><surname>Palotie</surname> <given-names>A</given-names></name><name><surname>Papamarkou</surname> <given-names>T</given-names></name><name><surname>Pomilla</surname> <given-names>C</given-names></name><name><surname>Pouta</surname> <given-names>A</given-names></name><name><surname>Rader</surname> <given-names>DJ</given-names></name><name><surname>Reilly</surname> <given-names>MP</given-names></name><name><surname>Ridker</surname> <given-names>PM</given-names></name><name><surname>Rivadeneira</surname> <given-names>F</given-names></name><name><surname>Rudan</surname> <given-names>I</given-names></name><name><surname>Ruokonen</surname> <given-names>A</given-names></name><name><surname>Samani</surname> <given-names>N</given-names></name><name><surname>Scharnagl</surname> <given-names>H</given-names></name><name><surname>Seeley</surname> <given-names>J</given-names></name><name><surname>Silander</surname> <given-names>K</given-names></name><name><surname>Stančáková</surname> <given-names>A</given-names></name><name><surname>Stirrups</surname> <given-names>K</given-names></name><name><surname>Swift</surname> <given-names>AJ</given-names></name><name><surname>Tiret</surname> <given-names>L</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>van Pelt</surname> <given-names>LJ</given-names></name><name><surname>Vedantam</surname> <given-names>S</given-names></name><name><surname>Wainwright</surname> <given-names>N</given-names></name><name><surname>Wijmenga</surname> <given-names>C</given-names></name><name><surname>Wild</surname> <given-names>SH</given-names></name><name><surname>Willemsen</surname> <given-names>G</given-names></name><name><surname>Wilsgaard</surname> <given-names>T</given-names></name><name><surname>Wilson</surname> <given-names>JF</given-names></name><name><surname>Young</surname> <given-names>EH</given-names></name><name><surname>Zhao</surname> <given-names>JH</given-names></name><name><surname>Adair</surname> <given-names>LS</given-names></name><name><surname>Arveiler</surname> <given-names>D</given-names></name><name><surname>Assimes</surname> <given-names>TL</given-names></name><name><surname>Bandinelli</surname> <given-names>S</given-names></name><name><surname>Bennett</surname> <given-names>F</given-names></name><name><surname>Bochud</surname> <given-names>M</given-names></name><name><surname>Boehm</surname> <given-names>BO</given-names></name><name><surname>Boomsma</surname> <given-names>DI</given-names></name><name><surname>Borecki</surname> <given-names>IB</given-names></name><name><surname>Bornstein</surname> <given-names>SR</given-names></name><name><surname>Bovet</surname> <given-names>P</given-names></name><name><surname>Burnier</surname> <given-names>M</given-names></name><name><surname>Campbell</surname> <given-names>H</given-names></name><name><surname>Chakravarti</surname> <given-names>A</given-names></name><name><surname>Chambers</surname> <given-names>JC</given-names></name><name><surname>Chen</surname> <given-names>YI</given-names></name><name><surname>Collins</surname> <given-names>FS</given-names></name><name><surname>Cooper</surname> <given-names>RS</given-names></name><name><surname>Danesh</surname> <given-names>J</given-names></name><name><surname>Dedoussis</surname> <given-names>G</given-names></name><name><surname>de Faire</surname> <given-names>U</given-names></name><name><surname>Feranil</surname> <given-names>AB</given-names></name><name><surname>Ferrières</surname> <given-names>J</given-names></name><name><surname>Ferrucci</surname> <given-names>L</given-names></name><name><surname>Freimer</surname> <given-names>NB</given-names></name><name><surname>Gieger</surname> <given-names>C</given-names></name><name><surname>Groop</surname> <given-names>LC</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Gyllensten</surname> <given-names>U</given-names></name><name><surname>Hamsten</surname> <given-names>A</given-names></name><name><surname>Harris</surname> <given-names>TB</given-names></name><name><surname>Hingorani</surname> <given-names>A</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Hovingh</surname> <given-names>GK</given-names></name><name><surname>Hsiung</surname> <given-names>CA</given-names></name><name><surname>Humphries</surname> <given-names>SE</given-names></name><name><surname>Hunt</surname> <given-names>SC</given-names></name><name><surname>Hveem</surname> <given-names>K</given-names></name><name><surname>Iribarren</surname> <given-names>C</given-names></name><name><surname>Järvelin</surname> <given-names>MR</given-names></name><name><surname>Jula</surname> <given-names>A</given-names></name><name><surname>Kähönen</surname> <given-names>M</given-names></name><name><surname>Kaprio</surname> <given-names>J</given-names></name><name><surname>Kesäniemi</surname> <given-names>A</given-names></name><name><surname>Kivimaki</surname> <given-names>M</given-names></name><name><surname>Kooner</surname> <given-names>JS</given-names></name><name><surname>Koudstaal</surname> <given-names>PJ</given-names></name><name><surname>Krauss</surname> <given-names>RM</given-names></name><name><surname>Kuh</surname> <given-names>D</given-names></name><name><surname>Kuusisto</surname> <given-names>J</given-names></name><name><surname>Kyvik</surname> <given-names>KO</given-names></name><name><surname>Laakso</surname> <given-names>M</given-names></name><name><surname>Lakka</surname> <given-names>TA</given-names></name><name><surname>Lind</surname> <given-names>L</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>März</surname> <given-names>W</given-names></name><name><surname>McCarthy</surname> <given-names>MI</given-names></name><name><surname>McKenzie</surname> <given-names>CA</given-names></name><name><surname>Meneton</surname> <given-names>P</given-names></name><name><surname>Metspalu</surname> <given-names>A</given-names></name><name><surname>Moilanen</surname> <given-names>L</given-names></name><name><surname>Morris</surname> <given-names>AD</given-names></name><name><surname>Munroe</surname> <given-names>PB</given-names></name><name><surname>Njølstad</surname> <given-names>I</given-names></name><name><surname>Pedersen</surname> <given-names>NL</given-names></name><name><surname>Power</surname> <given-names>C</given-names></name><name><surname>Pramstaller</surname> <given-names>PP</given-names></name><name><surname>Price</surname> <given-names>JF</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Quertermous</surname> <given-names>T</given-names></name><name><surname>Rauramaa</surname> <given-names>R</given-names></name><name><surname>Saleheen</surname> <given-names>D</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Sanghera</surname> <given-names>DK</given-names></name><name><surname>Saramies</surname> <given-names>J</given-names></name><name><surname>Schwarz</surname> <given-names>PEH</given-names></name><name><surname>Sheu</surname> <given-names>WH</given-names></name><name><surname>Shuldiner</surname> <given-names>AR</given-names></name><name><surname>Siegbahn</surname> <given-names>A</given-names></name><name><surname>Spector</surname> <given-names>TD</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name><name><surname>Strachan</surname> <given-names>DP</given-names></name><name><surname>Tayo</surname> <given-names>BO</given-names></name><name><surname>Tremoli</surname> <given-names>E</given-names></name><name><surname>Tuomilehto</surname> <given-names>J</given-names></name><name><surname>Uusitupa</surname> <given-names>M</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Vollenweider</surname> <given-names>P</given-names></name><name><surname>Wallentin</surname> <given-names>L</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Whitfield</surname> <given-names>JB</given-names></name><name><surname>Wolffenbuttel</surname> <given-names>BHR</given-names></name><name><surname>Ordovas</surname> <given-names>JM</given-names></name><name><surname>Boerwinkle</surname> <given-names>E</given-names></name><name><surname>Palmer</surname> <given-names>CNA</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Chasman</surname> <given-names>DI</given-names></name><name><surname>Rotter</surname> <given-names>JI</given-names></name><name><surname>Franks</surname> <given-names>PW</given-names></name><name><surname>Ripatti</surname> <given-names>S</given-names></name><name><surname>Cupples</surname> <given-names>LA</given-names></name><name><surname>Sandhu</surname> <given-names>MS</given-names></name><name><surname>Rich</surname> <given-names>SS</given-names></name><name><surname>Boehnke</surname> <given-names>M</given-names></name><name><surname>Deloukas</surname> <given-names>P</given-names></name><name><surname>Kathiresan</surname> <given-names>S</given-names></name><name><surname>Mohlke</surname> <given-names>KL</given-names></name><name><surname>Ingelsson</surname> <given-names>E</given-names></name><name><surname>Abecasis</surname> <given-names>GR</given-names></name><collab>Global Lipids Genetics Consortium</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Discovery and refinement of loci associated with lipid levels</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1274</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1038/ng.2797</pub-id><pub-id pub-id-type="pmid">24097068</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Würtz</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Soininen</surname> <given-names>P</given-names></name><name><surname>Kangas</surname> <given-names>AJ</given-names></name><name><surname>Fatemifar</surname> <given-names>G</given-names></name><name><surname>Tynkkynen</surname> <given-names>T</given-names></name><name><surname>Tiainen</surname> <given-names>M</given-names></name><name><surname>Perola</surname> <given-names>M</given-names></name><name><surname>Tillin</surname> <given-names>T</given-names></name><name><surname>Hughes</surname> <given-names>AD</given-names></name><name><surname>Mäntyselkä</surname> <given-names>P</given-names></name><name><surname>Kähönen</surname> <given-names>M</given-names></name><name><surname>Lehtimäki</surname> <given-names>T</given-names></name><name><surname>Sattar</surname> <given-names>N</given-names></name><name><surname>Hingorani</surname> <given-names>AD</given-names></name><name><surname>Casas</surname> <given-names>JP</given-names></name><name><surname>Salomaa</surname> <given-names>V</given-names></name><name><surname>Kivimäki</surname> <given-names>M</given-names></name><name><surname>Järvelin</surname> <given-names>MR</given-names></name><name><surname>Davey Smith</surname> <given-names>G</given-names></name><name><surname>Vanhala</surname> <given-names>M</given-names></name><name><surname>Lawlor</surname> <given-names>DA</given-names></name><name><surname>Raitakari</surname> <given-names>OT</given-names></name><name><surname>Chaturvedi</surname> <given-names>N</given-names></name><name><surname>Kettunen</surname> <given-names>J</given-names></name><name><surname>Ala-Korpela</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase</article-title><source>Journal of the American College of Cardiology</source><volume>67</volume><fpage>1200</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2015.12.060</pub-id><pub-id pub-id-type="pmid">26965542</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>JV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Coagulation factors and the risk of ischemic heart disease, a mendelian randomization study</article-title><source>Circulation. Genomic and Precision Medicine</source><volume>11</volume><elocation-id>001956</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCGEN.117.001956</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>JV</given-names></name><name><surname>Luo</surname> <given-names>S</given-names></name><name><surname>Schooling</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sex-specific mendelian randomization study of genetically predicted insulin and cardiovascular events in the UK biobank</article-title><source>Communications Biology</source><volume>2</volume><elocation-id>332</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-019-0579-z</pub-id><pub-id pub-id-type="pmid">31508506</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>JV</given-names></name><name><surname>Schooling</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of testosterone in chronic kidney disease and kidney function in men and women: a bi-directional mendelian randomization study in the UK biobank</article-title><source>BMC Medicine</source><volume>18</volume><elocation-id>122</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-020-01594-x</pub-id><pub-id pub-id-type="pmid">32493397</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58567.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewing Editor</role><aff><institution>University of Melbourne</institution><country>Australia</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Frayling</surname><given-names>Timothy</given-names> </name><role>Reviewer</role><aff><institution>University of Exeter Medical School</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The authors performed a Mendelian randomization analysis of statin, PCSK9 inhibitor and ezetimibe use on ischemic heart disease to address a clinically relevant question – could the apparent additional benefits of statins and other similar treatments, over and above lowering lipids, be mediated by favourable effects on testosterone levels? They found a potentially interesting link between statins and testosterone – genetic variants in the gene encoding the HMGcoR receptor that are known to alter LDL-cholesterol levels.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Pleiotropic effects of statins on ischemic heart disease: a Mendelian Randomization study in the UK Biobank&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Matthias Barton as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Timothy Frayling (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in <italic>eLife</italic> but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in <italic>eLife</italic>, either of which would be linked to the original paper.</p><p>Title: Please modify the title to comply with <italic>eLife</italic> requirements. The title should not exceed 120 characters. Two part titles containing a colon punctuation mark (&quot;:&quot;) are not allowed.</p><p>Summary:</p><p>This is a neat study using genetics to ask a clinically relevant question – could the apparent additional benefits of statins and other similar treatments, over and above lowering lipids, be mediated by favourable effects on testosterone levels? The question becomes a little more complicated in that higher levels of testosterone tend to be beneficial for men's metabolic health but adverse for women and so the authors have used UK Biobank data, where it is easy to stratify analyses by sex.</p><p>The authors performed a Mendelian randomization (MR) analysis of statin, PCSK9 inhibitor and ezetimibe use on ischemic heart disease (IHD), and if these effects were mediated by testosterone in men or women using univariable and multivariable MR.</p><p>They have found a potentially interesting link between statins and testosterone – genetic variants in the gene encoding the HMGcoR receptor that are known to alter LDL-cholesterol levels (And so we know they are very good mimics for the on target effects of statins) and testosterone levels in men. The direction is that the alleles associated with lower LDL-cholesterol and therefore mimic statins also lower testosterone. There were no links for the other genes encoding the other targets of lipid lowering therapy. In addition, they assessed whether the genetic variants corresponding to anti-inflammatory effects of anakinra or tocilizumab use had effects on testosterone and IHD. The topic is very interesting.</p><p>Revisions for this paper:</p><p>1) The main finding is that, when adjusting for testosterone levels, the protective benefit of statins via the HMGcoR on heart disease attenuates from 0.54 odds ratio to 0.73 in men (when using the MR egger approach. There are wide 95% CIs around these estimates but the results imply that the testosterone effect is similar to the lowering LDL-cholesterol effect, which is extremely counter intuitive given that we know about LDL-cholesterol and heart disease. The reliance on a sensitivity analysis – MR egger – when the main analysis showed evidence of pleiotropy means the results could be very sensitive to slight differences in the parameters used. (SNPs and models).</p><p>2) A second concern is that the genetic variants in HMGCoR are associated with BMI and adiposity (see Swerdlow et al. Lancet publication using the HMGcoR SNPs to show an association with diabetes) whereas the others are less so. The authors need to assess the potential for the effect being mediated via BMI/adiposity rather than testosterone. Such a mechanism would be consistent with sex differences because women are at lower risk of heart disease than men for a given BMI. Likewise, many of the testosterone SNPs are highly pleiotropic, with many primarily associated with adiposity and insulin resistance and lipid levels. My concern is that the pleiotropy will lead to false inferences. The authors have partially addressed this with some approaches such as MR-Egger, but these are not infallible. The multivariable MR needs to include the adiposity measures. multivariable MR with adiposity measures, steiger filtering of SNPs that have larger effects on metabolic potentially mediating traits than they do on lipids or testosterone could be alternative approaches to try.</p><p>3) It would be relevant to see the results replicated in a two sample MR setting where the IHD cases are not from the same dataset as the testosterone and LDL SNPs. The heart disease GWAS consortia have not analysed separately by sex, which makes this very difficult, but there may be other large studies where this is possible ? If this cannot be done readily it should be discussed and noted as a limitation.</p><p>4) All of this means that the conclusion that &quot;statins partially operate on IHD by reducing testosterone in men&quot; is likely overstated.</p><p>5) A further major concern is the selection of SNPs in vicinity of the <italic>HMGCR</italic>, <italic>NCP1L1</italic> and <italic>PCSK9</italic> genes as instruments for the statin, PCSK9 and ezetimibe use, respectively. For example, a lookup of the instrument included for ezetimibe use (rs10260606) in the publicly available sex-combined GWAS on ezetimibe treatment (http://www.nealelab.is/uk-biobank) resulted in an association p-value of 0.02 being a rather weak instrument. Also in the referenced publication of Ference et al., 2019, that was used as basis for the instrument selection, these SNPs were (to my understanding) selected to assess potential drug targets, and not to reflect medication use.</p><p>6) Which statistical model was used to calculate the sex-specific genetic associations with IHD (I assume logistic regression)? Please provide the number of cases and controls per sex-stratum that were finally included in this association analysis also in the main text (not only in the Abstract).</p><p>Please provide the p-value level that was applied to declare significance of the results.</p><p>7) By conducting a sex-stratified analyses, have the authors considered the impact of collider bias. As if the genetic instruments are associated with sex and the outcome measures are also associated with sex, by stratifying based on a common cause of the exposure and outcome, a distorted/erroneous association may occur.</p><p>8) Please give more details about multivariate MR analysis. E.g. did you pool the genetic proxies for statin and testosterone all together and then extracted the associations of all these SNPs with LDL-cholesterol and testosterone and fitted it in one model?</p><p>Revisions expected in follow-up work:</p><p>1) As the authors aim to investigate sex-specific benefits of statin therapies, why only focus on testosterone. I think you should also look at 17β-oestradiol and SHBG (both available in UKBB), and conduct a multivariate MR to determine which would be the independent causal factor for IHD among the three (e.g. PMID: 32203549) and then forward the independent hormones/proteins in a multivariate model with LDL-cholesterol or apoB (drug targets of lipid lowering drugs) to determine whether these hormones would exert independent roles in contributing to IHD beyond the lipids. If this is the case, then it makes sense to further determine whether the genetic instruments of the drug targets show a sex-specific association with the sex hormones. This issue could be addressed in the Discussion.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58567.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Revisions for this paper:</p><p>1) The main finding is that, when adjusting for testosterone levels, the protective benefit of statins via the HMGcoR on heart disease attenuates from 0.54 odds ratio to 0.73 in men (when using the MR egger approach. There are wide 95% CIs around these estimates but the results imply that the testosterone effect is similar to the lowering LDL-cholesterol effect, which is extremely counter intuitive given that we know about LDL-cholesterol and heart disease. The reliance on a sensitivity analysis – MR egger – when the main analysis showed evidence of pleiotropy means the results could be very sensitive to slight differences in the parameters used. (SNPs and models).</p></disp-quote><p>Please accept our apologies for a counter-intuitive finding. We are in no way trying to question the role of LDL-cholesterol in heart disease. We are instead trying to address two important health issues. First, the higher rates of heart disease in men than women,<sup>1</sup> which are a factor contributing to shorter life expectancy in men than women. Second, the apparent pleiotropic effects of statins, because their explication might facilitate the discovery of much needed new treatments for cardiovascular disease.</p><p>As regards, the size of the estimates for statins via HMGcoR on ischemic heart disease (IHD). After allowing for testosterone, the estimates in men changed from being larger than the estimates in women to being very similar to the estimates in women, as expected. However, we agree that the magnitude of the estimates in Mendelian randomization (MR) is difficult to interpret because MR estimates capture lifetime effects rather than a possibly short-term exposure. We have clarified this important point to the Discussion, by making the following change:</p><p>From: “Lastly, Mendelian randomization assesses the lifelong effects of an endogenous exposure rather than short-term effects of an interventions assessed in an RCT, nevertheless our estimates for statins on IHD are comparable with meta-analyses of statin trials considering similar outcomes.<sup>2</sup>”</p><p>To: “Lastly, Mendelian randomization assesses the lifelong effects of an endogenous exposure rather than short-term effects of an interventions assessed in an RCT. Our estimates give an indication of the role of the exposures rather than the exact effects of the corresponding interventions. Nevertheless, our estimates for genetically mimicked statins on IHD are comparable with meta-analyses of statin trials considering similar outcomes.<sup>2</sup> ”</p><p>Please accept our apologies for being unclear about the use of the MR-Egger estimate. For univariable mendelian randomization (MR), MR-Egger is a sensitivity analysis. For the multivariable MR, when the analysis is multivariable by design with few genetic variants specifically predicting the exposures, as here for statins, then the MR-Egger estimate is most likely to be reliable.<sup>3</sup> It is also recommended to use the MR-Egger multivariable estimate when the multivariable MR-Egger intercept is significant,<sup>3</sup> as here. We have added this point to the Materials and methods:</p><p>“Given this analysis is multivariable by design with few genetic variants available to mimic the effects of statins, we used the multivariable MR-Egger estimates<sup>3</sup>.”</p><p>We also amended the Results to be clearer by making the following change:</p><p>From: “Correspondingly, the multivariable MR-Egger intercepts were significant in men and women, so we used the MR-Egger estimates <sup>3</sup>.”</p><p>To: “Correspondingly, the multivariable MR-Egger intercepts were significant in men and women.”</p><disp-quote content-type="editor-comment"><p>2) A second concern is that the genetic variants in HMGCoR are associated with BMI and adiposity (see Swerdlow et al. Lancet publication using the HMGcoR SNPs to show an association with diabetes) whereas the others are less so. The authors need to assess the potential for the effect being mediated via BMI/adiposity rather than testosterone. Such a mechanism would be consistent with sex differences because women are at lower risk of heart disease than men for a given BMI. Likewise, many of the testosterone SNPs are highly pleiotropic, with many primarily associated with adiposity and insulin resistance and lipid levels. My concern is that the pleiotropy will lead to false inferences. The authors have partially addressed this with some approaches such as MR-Egger, but these are not infallible. The multivariable MR needs to include the adiposity measures. multivariable MR with adiposity measures, steiger filtering of SNPs that have larger effects on metabolic potentially mediating traits than they do on lipids or testosterone could be alternative approaches to try.</p></disp-quote><p>Thank you very much indeed for raising these concerns as to whether the pleiotropic effects of statins are via BMI rather than testosterone. We have considered this possibility in detail.</p><p>First, we checked, as expected from Swerdlow,<sup>4</sup> that statins increase BMI in men and women (beta 0.33 effect size, 95% confidence interval (CI) 0.20 to 0.47, in men and 0.31, 95% CI 0.22 to 0.40, in women, Author response table 1 below), using published instruments for BMI<sup>5</sup> and rs12916-T to mimic effects of statins, and the UK Biobank sex-specific genetic associations with BMI (http://www.nealelab.is/uk-biobank).</p><p>Second, we considered the effect of BMI<sup>5</sup> and genetically mimicked statins on IHD in univariable and multivariable MR. In univariable MR, as expected, BMI increased IHD (odds ratio (OR) 1.33, 95% confidence interval (CI) 1.15 to 1.55, in men and OR 1.23, 95% CI 1.02 to 1.48, in women) and genetically mimicked statins decreased IHD (OR 0.54, 95% CI 0.38 to 0.79 in men and had an estimate in the same direction in women OR 0.87, 95% CI 0.59 to 1.27, Author response table 1). In multivariable MR, considering the effects of BMI and genetically mimicked statins (rs12916-T) together on IHD, BMI had very similar associations with IHD as in the univariable analysis (OR 1.35, 95% CI 1.15 to 1.57 in men and women OR 1.27, 95% CI 1.07 to 1.52). In contrast, in the multivariable analysis including BMI genetically mimicked statins had a larger decreasing effect on IHD (OR 0.46, 95% CI 0.35 to 0.65 in men and OR 0.68, 95% CI 0.53 to 0.86 in women). As such, the protective effect of statins on IHD was increased by additionally considering BMI, so statins protective effect on IHD does not appear to be explained away by statins increasing BMI, in fact including BMI makes the protective effects of statins on IHD more marked. The multivariable MR is probably giving a larger effect size for statins than the univariable MR because it is showing the effects of “statins” after removing the harmful aspect driven by raising BMI. As such, statins raising BMI is unlikely to be a pathway by which statins protect against IHD, and we did not consider it further in the multivariable MR to keep the paper as simple and focused as possible. We have added this point in the Discussion as follows:</p><p>“We did not include body mass index (BMI) as a risk factor explaining the effect of mimicking statins on IHD, because statins increase BMI<sup>4</sup> and decrease the risk of IHD, so including them in the multivariable analysis may inflate the effect of mimicking statins on IHD, rather than explaining part of the effect”.</p><p>We agree that the testosterone SNPs may have pleiotropic effects possibly acting via adiposity, insulin resistance or lipids. Downstream effects of the exposures help explain how the exposure affects the outcome. Downstream effects of the exposures generate vertical pleiotropy which does not bias MR estimates, because it is a pathway through the exposure, rather than the genetic instrument operating by a pathway distinct from the exposure. Pleiotropy biases MR estimates, when it is horizontal pleiotropy, and the genetic instrument affects the outcome by a pathway distinct from the exposure. We also checked whether the testosterone SNPs operated via adiposity or lipids. The testosterone SNPs did not affect BMI in men, consistent with a previous Mendelian randomization study,<sup>6</sup> as given below (Author response table 2). In contrast testosterone raised BMI in women and reduced LDL-cholesterol, however, testosterone in women does not affect IHD. We have added that these points in the Discussion.</p><p>“Testosterone’s effects on IHD in men could be via adiposity, insulin or LDL-cholesterol rather than via testosterone. […] We could not test whether testosterone in men affects insulin because of the lack of an insulin GWAS including the X chromosome.”</p><p>Author response table 1: Univariable Mendelian randomization estimates for genetically mimicked statins (rs21916-T) and genetically predicted BMI (95 variants*) on IHD in men and women in the UK Biobank.</p><p>*after removing one variant predicting BMI (rs2112347) that was correlated with rs12916</p><p>Author response table 2: Univariable sex-specific Mendelian randomization estimates for testosterone on body mass index and LDL-cholesterol in men and women in the UK Biobank.</p><p>As suggested, we used Steiger filtering to check the direction from testosterone to IHD,<sup>7</sup> which confirmed that the direction of causality was from testosterone to IHD in men and women. We have added this point in the Materials and methods and the Results.</p><p>In the Materials and methods:</p><p>“Steiger filtering was used to check the directionality between testosterone and IHD.<sup>7</sup>”</p><p>In the Results;</p><p>“Steiger filtering indicated directionality from testosterone to IHD in men and women.”</p><disp-quote content-type="editor-comment"><p>3) It would be relevant to see the results replicated in a two sample MR setting where the IHD cases are not from the same dataset as the testosterone and LDL SNPs. The heart disease GWAS consortia have not analysed separately by sex, which makes this very difficult, but there may be other large studies where this is possible ? If this cannot be done readily it should be discussed and noted as a limitation.</p></disp-quote><p>Please accept our apologies for being unclear. The testosterone SNPs were derived from the UK Biobank, but were also replicated in three independent studies,<sup>8</sup> so they do have some replication. The LDL SNPs for statins, PCSK9 inhibitors and ezetimibe do not come from the same dataset as the IHD cases. The LDL SNPs come from Ference et al., as used previously to mimic the effects of lipid modifiers<sup>9</sup>. Only the beta co-efficients for the LDL SNPs on LDL come from the same study as the IHD cases. The beta coefficients are simply scaling factors which are quite similar to those from the Global Lipids Genetic consortium (GLGC), as we show in Supplementary file 1. We have added a column to that table to make it clearer. However, the GLGC does not have sex-specific genetic associations with LDL-c, so we used UK Biobank which gives sex-specific effect of the SNPs mimicking statins on LDL-c. We have explained this point, as given below:</p><p>“Strong (p-value&lt;5×10<sup>-8</sup>), independent (r<sup>2</sup>&lt;0.05), sex-specific genetic predictors of testosterone were extracted from a published genome wide association study (GWAS) based on the UK Biobank and replicated in three independent studies (CHARGE Consortium, Twins UK and EPIC-Norfolk) <sup>10 11</sup>.”</p><p>“Genetic effects mimicking statins, PCSK9 inhibitors and ezetimibe were expressed in sex-specific effect sizes of LDL-cholesterol reduction taken from the largest available sex-specific GWAS summary statistics, i.e., the UK Biobank (http://www.nealelab.is/uk-biobank).”</p><p>Thank you for this suggestion about replication, we would be very keen to do so. We cannot identify any other sex-specific GWAS of IHD. Most GWAS of IHD are composed largely of men, so one option would be to repeat the analysis using an IHD GWAS of mainly men. However, there are two issues with that approach. First a GWAS of mainly men does not provide replication by sex. Second, almost all previous GWAS are autosomal, so we are missing key items in the testosterone instrument from the X chromosome, which means this is not a true replication. We have clarified this point in the Discussion, by making the following change:</p><p>From: “Replication based on another large IHD GWAS, such as CARDIoGRAM<sup>12</sup>, would be ideal, but it is less intensively genotyped than the UK Biobank and excludes the X chromosome, making it unsuitable.”</p><p>To: “Replication based on another large sex-specific IHD GWAS where the IHD cases are not from the same study as the testosterone instruments, would be ideal. However, sex-specific summary statistics are not available for large existing IHD GWAS, such as CARDIoGRAM.<sup>12</sup> Moreover, the UK Biobank has the advantage of being very intensively genotyped and including the X chromosome, which is important for testosterone, but is not usually included in publicly available summary statistics. Lack of replication is a limitation of this study.”</p><disp-quote content-type="editor-comment"><p>4) All of this means that the conclusion that &quot;statins partially operate on IHD by reducing testosterone in men&quot; is likely overstated.</p></disp-quote><p>We fully accept that no study is ever definitive, so we have amended this sentence to say</p><p>“statins could partially operate on IHD by reducing testosterone in men&quot;.</p><disp-quote content-type="editor-comment"><p>5) A further major concern is the selection of SNPs in vicinity of the HMGCR, NCP1L1 and PCSK9 genes as instruments for the statin, PCSK9 and ezetimibe use, respectively. For example, a lookup of the instrument included for ezetimibe use (rs10260606) in the publicly available sex-combined GWAS on ezetimibe treatment (http://www.nealelab.is/uk-biobank) resulted in an association p-value of 0.02 being a rather weak instrument.</p></disp-quote><p>Thank you for these comments. Please accept our apologies for being unclear, we did not obtain the instruments for statins, PCSK9 or ezetimibe use from the UK Biobank GWAS of self-reports of drug use. There were three reasons for this choice. First, for comparability with other studies we used instruments from a previous study.<sup>9</sup> Second, self-reports are not always very reliable, so a GWAS based on self-reports may generate instruments that represent noise rather than signal. This may be why MR studies exploring the effects of medications usually use genetic predictors related to the drug target, based on biological pathways so as to minimise potential bias. Third, the SNPs for statins, PCSK9 or ezetimibe are to some extent selected on functional rather than statistical grounds from relevant genes which encode proteins targeted by these drugs. This approach has the advantage of being functionally relevant, and so hopefully is relevant to the drugs biological effect, and shows the effect of the drug. The SNPs we used all had F-statistics greater than 10. On reflection, we realize that the language used to describe exposure was unclear as “effects of statin use” and we have amended it throughout, from “effects of statin use”, to “mimic the effect of statins” or similar. Thank you for pointing this out.</p><disp-quote content-type="editor-comment"><p>Also in the referenced publication of Ference et al., 2019, that was used as basis for the instrument selection, these SNPs were (to my understanding) selected to assess potential drug targets, and not to reflect medication use.</p></disp-quote><p>Thank you for these comments. As noted in the previous comment, we found it very tricky to find exactly the right words to describe the instruments for statins, PCSK9 inhibitors and ezetimibe clearly. We have carefully reviewed the underlying publications to find more appropriate wording to describe use of these variants in similar situations. As given below the original publications use the words “mimic the effect of [the drug] or “as a proxy for [drug] treatment”.</p><p>Ference et al., 2019, used the wording “Genetic variants that mimic the effect of …statins”<sup>9</sup>.</p><p>Ference et al., 2016, used the wording “We constructed genetic scores that mimic the effect of PCSK9 inhibitors and the effect of statins”<sup>13</sup>.</p><p>Ference et al., 2015, used the wording “To compare the biological effect of lower LDL-cholesterol mediated by inhibition of <italic>NCP1L1</italic>, <italic>HMGCR</italic>, or both on the risk of CHD, and to provide a context for interpreting the results of IMPROVE-IT, we sought to compare the effect of naturally random allocation to lower LDL-cholesterol on the risk of CHD mediated by genetic polymorphisms in the NPC1L1 gene (as a proxy for ezetimibe treatment), the <italic>HMGCR</italic> gene (as a proxy for statin treatment)”.</p><p>We have amended the paper throughout to be consistent with the previous usage and to use the expression “mimic the effect of” or similar throughout.</p><disp-quote content-type="editor-comment"><p>6) Which statistical model was used to calculate the sex-specific genetic associations with IHD (I assume logistic regression)? Please provide the number of cases and controls per sex-stratum that were finally included in this association analysis also in the main text (not only in the Abstract).</p></disp-quote><p>Thank you for pointing out this oversight, we have added that the associations with IHD were “obtained using logistic regression”. Information about the number of cases is given in the main text.</p><disp-quote content-type="editor-comment"><p>Please provide the p-value level that was applied to declare significance of the results.</p></disp-quote><p>We have added this point in the text:</p><p>“Given this is a hypothesis driven study, with a positive control, we used a statistical significance level of 0.05.”</p><disp-quote content-type="editor-comment"><p>7) By conducting a sex-stratified analyses, have the authors considered the impact of collider bias. As if the genetic instruments are associated with sex and the outcome measures are also associated with sex, by stratifying based on a common cause of the exposure and outcome, a distorted/erroneous association may occur.</p></disp-quote><p>Thank you very much indeed for raising the issue of collider bias. Stratifying on a common cause of exposure and outcome is typically used to address confounding, i.e., it removes bias rather than adds bias.<sup>14</sup> Collider bias (or selection bias) typically occurs if there is selection (or stratification) on a common effect of the exposure and outcome,<sup>14</sup> i.e., here the genetic variants and IHD. We do not think that sex is a result of the genetic variants or of IHD and hence collider bias is very unlikely upon stratification by sex.</p><disp-quote content-type="editor-comment"><p>8) Please give more details about multivariate MR analysis. E.g. did you pool the genetic proxies for statin and testosterone all together and then extracted the associations of all these SNPs with LDL-cholesterol and testosterone and fitted it in one model?</p></disp-quote><p>Please accept our apologies for not explaining these points clearly. This is exactly the process we carried out. We have added this point, as follows:</p><p>“In the multivariable MR, we pooled the genetic instruments mimicking statins and the genetic instruments for testosterone together, extracted their associations with LDL-cholesterol and testosterone and fitted one multivariable model.”</p><disp-quote content-type="editor-comment"><p>Revisions expected in follow-up work:</p><p>1) As the authors aim to investigate sex-specific benefits of statin therapies, why only focus on testosterone. I think you should also look at 17β-oestradiol and SHBG (both available in UKBB), and conduct a multivariate MR to determine which would be the independent causal factor for IHD among the three (e.g. PMID: 32203549) and then forward the independent hormones/proteins in a multivariate model with LDL-cholesterol or apoB (drug targets of lipid lowering drugs) to determine whether these hormones would exert independent roles in contributing to IHD beyond the lipids. If this is the case, then it makes sense to further determine whether the genetic instruments of the drug targets show a sex-specific association with the sex hormones. This issue could be addressed in the Discussion.</p></disp-quote><p>Thank you very much indeed for asking why we focused on testosterone. We have for many years been examining the theory that statins operate specifically by testosterone,<sup>15 16</sup> as presented explicitly in Figure 1 of the paper. In contrast, we have not been investigating the role of estrogen in IHD. Large randomized controlled trials have shown that hormone replacement therapy in women does not protect against IHD,<sup>17</sup> and estrogen does not protect against IHD in men.<sup>18</sup> Nevertheless, the possibility of a role of estrogen in IHD remains, because hormone replacement therapy may differ from naturally occurring estrogen in women and in men the Coronary Drug project estrogen arms were stopped early. Sex hormone binding globulin (SHBG) could be an independent influence on IHD or an important moderator of the role of testosterone, which deserves investigation. However, as shown in Author response table 3 (below) estrogen and SHBG do not seem relevant to specifically the effects of statins on IHD in men.</p><p>Author response table 3: Mendelian randomization estimates for effects of genetically mimicked statins (per effect sizes of LDL-cholesterol) on estrogen and SHBG in men and women from the UK Biobank summary statistics (<ext-link ext-link-type="uri" xlink:href="http://www.nealelab.is/uk-biobank">http://www.nealelab.is/uk-biobank</ext-link>).</p><p>The unit of LDL-cholesterol is approximately 0.83mm/L.</p><p>We agree completely that it is a very important question to assess the independent role of testosterone, 17β-oestradiol and SHBG in IHD by sex and the extent to which they operate via LDL-cholesterol or apoB. Currently there is a dearth of comprehensive genetic instruments for estrogen. Ruth et al., by far the largest GWAS of sex hormones, only provided genetic instruments for estrogen in men, but not for estrogen in women.<sup>19</sup> We have explained this future work in the Discussion as follows.</p><p>“Here, we present a hypothesis driven study examining the role of testosterone in mediating the effect of specifically statins in IHD, particularly in men. Future work could encompass a comprehensive sex-specific multivariable MR to confirm the role of sex hormones and sex hormone binding globulin in IHD as well as any mediation of their effects by key lipids, such as LDL-cholesterol or apoB. This work would be facilitated by the development of published genetic instruments for estrogen in women.</p><p>References:</p><p><ext-link ext-link-type="uri" xlink:href="https://wwwbiorxivorg/content/101101/660506v1">https://wwwbiorxivorg/content/101101/660506v1</ext-link></p><p>1) Moran AE, Tzong KY, Forouzanfar MH, et al. Variations in ischemic heart disease burden by age, country, and income: the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart 2014;9(1):91-9. doi: 10.1016/j.gheart.2013.12.007 [published Online First: 2014/07/01]2) Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London, England) 2015;385(9976):1397-405. doi: 10.1016/s0140-6736(14)61368-4 [published Online First: 2015/01/13]3) Rees JMB, Wood AM, Burgess S. Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy. Stat Med 2017;36(29):4705-18. doi: 10.1002/sim.7492 [published Online First: 2017/09/30]4) Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet (London, England) 2015;385(9965):351-61. doi: 10.1016/s0140-6736(14)61183-1 [published Online First: 2014/09/30]5) Larsson SC, Bäck M, Rees JMB, et al. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. European heart journal 2020;41(2):221-26. doi: 10.1093/eurheartj/ehz388 [published Online First: 2019/06/14]6) Eriksson J, Haring R, Grarup N, et al. Causal relationship between obesity and serum testosterone status in men: A bi-directional mendelian randomization analysis. PLoS One 2017;12(4):e0176277. doi: 10.1371/journal.pone.0176277 [published Online First: 2017/04/28]7) Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS genetics 2017;13(11):e1007081. doi: 10.1371/journal.pgen.1007081 [published Online First: 2017/11/18]8) Rafiq S, Frayling TM, Murray A, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun 2007;8(7):552-9. doi: 10.1038/sj.gene.6364414 [published Online First: 2007/08/03]9) Ference BA, Ray KK, Catapano AL, et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease. The New England journal of medicine 2019;380(11):1033-42. doi: 10.1056/NEJMoa1806747 [published Online First: 2019/03/14]10) Ruth KS, Day FR, Tyrrell J, et al. Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med 2020;26(2):252-58. doi: 10.1038/s41591-020-0751-511) Sinnott-Armstrong N, Tanigawa Y, Amar D, et al. Genetics of 38 blood and urine biomarkers in the UK Biobank. 201912) Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nature genetics 2015;47(10):1121-30. doi: 10.1038/ng.3396 [published Online First: 2015/09/08]13) Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. The New England journal of medicine 2016;375(22):2144-53. doi: 10.1056/NEJMoa1604304 [published Online First: 2016/12/14]14) Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15(5):615-25. doi: 10.1097/01.ede.0000135174.63482.43 [published Online First: 2004/08/17]15) Schooling CM, Au Yeung SL, Freeman G, et al. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57. doi: 10.1186/1741-7015-11-57 [published Online First: 2013/03/02]16) Schooling CM, Au Yeung SL, Leung GM. Why do statins reduce cardiovascular disease more than other lipid modulating therapies? Eur J Clin Invest 2014;44(11):1135-40. doi: 10.1111/eci.12342 [published Online First: 2014/09/25]17) Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Jama 2013;310(13):1353-68. doi: 10.1001/jama.2013.278040 [published Online First: 2013/10/03]18) The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. Jama 1973;226(6):652-7. [published Online First: 1973/11/05]19) Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nature genetics 2013;45(11):1274-83. doi: 10.1038/ng.2797 [published Online First: 2013/10/08]et al.</p></body></sub-article></article>